,ticker,content
0,ZBH,hurricane harvey irma marium didn just devastate texas florida puerto rico medtech player medtronic mdt group medical group wmgi be flail headwind monday xin afternoon trading stock market today ibd company medical product industry group medtronic lead market cap fall collective medtronic acknowledge impact hurricane have quarterly metric win be alone rbc analyst glenn novarro write note client news report indicate puerto rico hospital be not operational end third quarter be operational not have be run full capacity say assume lose week procedure end third quarter puerto rico device manufacturer say also conservatively estimate elective procedure be perform puerto rico fourth quarter friday medtronic say expect impact revenue earning fiscal second quarter firm say too early determine be impact latter half year least analyst cut price target stock follow medtronic monday pre announce negative result sustain least price target haircut quarter expect report sale vs year earlier period analyst view firm also trim sale outlook grow share be hardest hit medical product group plunge close monday nuvasive nuva globus medical gmed make medical implant dove respective novarro say be opportunity investor nuvasive nuvasive be capable accelerate organic revenue growth fourth quarter have strong product portfolio operate margin expansion opportunity say expect management team cut guidance due hurricane related revenue shortfall sell past several week be already discounting say nuvasive be deal specific short term issue setup look attractive separate report pre announcement novarro note investor sentiment spine stock remain negative cut price target keep outperform rating say be buyer pullback stock worst be already price argue needham analyst mike matson be more bearish still spine player outside hurricane be impact weaker degenerative deformity procedure growth august september matson write note client likely globus nuvasive miss estimate third quarter matson lower view now see earlier expectation also trim price target keep strong buy rating medtronic topple month low monday series price target cut announce hurricane marium damage puerto rico hit earning revenue also last week zimmer biomet zbh say hurricane be headwind third quarter earning novarro expect abbott laboratory boston scientific bsx chip away sale medtronic implantable heart device several newly launch product be back order status have lower inventory level hurricane firm say press release ibd take medtronic have ibd composite rating best possible meaning underperform more half stock term key growth metric head ibd stock checkup look stronger performer competitor be able take advantage such supply shortage be hard quantify stage novarro say therefore see downside risk revenue earning guidance second half second fiscal quarter novarro trim model sale cent earning share novarro also slash view fiscal model sale earning share forecast ep sale fiscal result price target cut novarro keep outperform rating least other analyst cut price target medtronic stock well fargo downgrade medtronic market perform outperform medtronic topple finish dow component johnson johnson jnj appear sustain minimal damage janssen unit gurabo facility make remicade xarelto prezista number other drug accord ub analyst carter view satellite image facility base utilization most lot site appear activity be return facility write note client fellow drugmaker amgen amgn have visible damage roof building flood access road manufacturing site puerto rico oct roof appear have be fix parking lot be capacity say amgen confirm used diesel generator site contract fuel provider have be make shipment meantime first shipment inventory puerto rico have already fly island say unlikely food drug administration require inspection allow amgen restart production ultimately expect accounting charge related be incrementally less concern potential disruption product supply say related medtronic sink sale lag earning beat robotic player near then topple here drug bellwether sale miss actually bode well sector
1,ZBH,david dvorak departure zimmer biomet zbh be likely excite stock analyst say chief executive exit be announce disappointing second quarter metric tuesday needham analyst mike matson call second quarter disappointment dvorak third strike zimmer note trouble plant warsaw ind increase output second quarter production certain brand still fall short expectation have trouble recover market share lose prior month write note client still matson keep strong buy rating price target zimmer stock zimmer biomet stock dip fraction stock market today earlier trading session be much share remain buy zone hit buy point early june cup handle base begin form october dvorak have head zimmer departure follow recent exit other manager include senior vice president vice president quality assurance interim senior vice president chief financial officer dan florin take dvorak place rbc analyst glenn novarro imagine zimmer look outside firm recruit new chief executive officer search span quarters say ibd take zimmer stock have ibd composite rating meaning have outperformed more quarters stock key growth metric past month see better rate stock ibd stock checkup announcement dvorak exit follow disappointing second quarter pre announcement period zimmer report sale fraction year year zimmer also say expect adjust income come low end share guidance company didn adjust guidance novarro be uncertain company meet initial guide give continue supply issue uncertainty associate leadership change recent lack new product innovation longer have confidence management guidance return market revenue growth second half write novarro have outperform rating price target zimmer stock related medtech stock crash technical level get
2,ZBH,bellwether johnson johnson jnj second quarter report bode well biotech sector analyst say tuesday dow component top profit expectation narrowly lag sale view stock market today stock climb biotech stock drop nearly group generic drugmaker inched leerink analyst geoffrey porge remain bullish biotech sector needham analyst mike matson say second quarter result point stable period medtech player boston scientific bsx medtronic mdt stryker syk zimmer biomet zbh quarter drug sale grow sequentially fall vs year earlier period porge partially blame time positive rebate adjustment eliminate year year volume price growth second quarter sale remicade decline year year rivalry biosimilar contribute just decline be lower guidance decline porge write note client ibd take cancer rare disease specialist be expect do well second half positive sentiment return biotech space visit ibd industry snapshot look outperform second quarter also expect currency headwind subside second half call acceleration pharmaceutical unit well positive trend sale outside base presume currency impact firm raise outlook adjust profit share outside drug sale grow sequentially second quarter beating view growth porge say support expectation sequential outside revenue growth company due weaken dollar second quarter say porge expect guidance increase biotechs second quarter earlier week call regeneron pharmaceutical regn easily beat june quarter sale view gilead science gild handily top profit expectation cover company not be negatively impact same prior period adjustment current imminent biosimilar competition surprise consensus remicade market dynamic be view proxy say abbvie abbv see pain sale cancer drug imbruvica grow outside say be partner abbvie imbruvica typically book imbruvica sale porge say translate abbvie imbruvica sale be miss vs consensus estimate say abbvie imbruvica be consider largest growth driver humira patent cliff continue miss consensus expectation repeat second quarter be negative stock related star align biotechs crush earning consensusthese drug giant buy range just beat earning novartis fda cancer also be boon rival
3,ZBH,zimmer biomet zbh share gap sharply thursday beating first quarter forecast musculoskeletal device maker shrank guidance year orthopedic device maker now expect full year revenue rise notch prior outlook upper end adjust share profit get significant haircut now see vs previous view analyst be currently forecasting ep revenue zimmer share plunge low stock market today tumble month high entry point cup handle base gapping day day move average zimmer pare loss still hefty close session high first quarter warsaw ind base company post profit gain share revenue growth top estimate share sale ahead earning report zimmer have be peg rbc analyst hot medtech stock own johnson johnson jnj other related medtech stock buy ahead medtronic edward best stock own analyst
4,ZBH,johnson johnson jnj zimmer biomet zbh be medtech stock own go earning season several other be put buy list pullback analyst say rbc analyst glenn novarro say wednesday large cap medtech stock johnson zimmer offer best risk reward first quarter earning season zimmer be cheapest arena johnson have lag group investor sentiment have turn more favorable johnson recent week anticipate further multiple expansion back strong first quarter result consensus estimate move higher year write research report consensus analyst poll yahoo yhoo broadly expect johnson report sale year year share adjust earning dip johnson be also cusp close acquisition actelion pharmaceutical second quarter sanofi sny be lock battle late last year take swiss biotech johnson bid win company zimmer company just have hit consensus estimate stock move higher novarro say consensus model year year sale growth adjust earning share novarro however say abbott laboratory boston scientific bsx edward lifescience ew stryker syk be attractive pullback see deliver solid result reaffirm guidance investor likely track ongoing litigation abbott alere alr heart valve replacement sale edward boston likely comment voluntary recall lotus heart valve replacement company recall lotus device discover malfunction result premature release pin implantation medtronic mdt onyx stent launch represent term challenge boston still want own boston novarro say small midsize cap world novarro recommend nuvasive nuva medical group wmgi group potential takeout be likely baked stock price nuvasive say ibd take isn first time edward have be list best stock own head ibd technology page deeper dive edward be hold strong remain top pick small midsize medtech group expect play catch group investor focus shift company impressive new product lineup improve international sale growth company experience distributor issue write novarro needham analyst mike matson also prefer zimmer also have strong buy rating share inogen ingn mimedx mdxg see cardiovascular orthopedic market slow diagnostic market improve quarter matson model cardiovascular market growth decelerate fourth quarter orthopedic market advance vs growth prior quarter diagnostic sale likely grow say be standout matson say model transcatheter aortic valve replacement market boston edward medtronic operate have grow orthopedic matson model growth extremity market related medtronic do heart valve study rival reap benefitsboston scientific make acquisition battle medtronic edward
5,ZBH,medtronic mdt edward lifescience ew stock dip monday series bullish report include call heart valve replacement rival stock own term midday trading share medtronic end virtually flat stock market today edward close rbc analyst glenn novarro expect have strong catalyst term note client sunday novarro say see edward medtronic stryker syk zimmer biomet zbh group stock own term call edward medtronic best idea cardiovascular work heart valve replacement recent study medtronic show new method insert heart valve be superior open heart surgery be encourage novarro say result help stoke growth transcatheter aortic valve replacement market say check ibd best mutual fund awardsfollow novarro report evercore analyst vijay kumar upgrade edward stock buy rating raise price target needham analyst mike matson reiterate buy rating price target medtronic stock matson expect medtronic maintain mid single digit sale growth double digit earning growth overcome temporary product cycle competitive issue fiscal third quarter believe medtronic product cycle remain very strong effectively fend competitive product launch investor concern matson write note client medtronic compete edward lifescience smaller outfit heart valve replacement boston scientific bsx also be look break transcatheter aortic valve replacement market doesn yet have fda approval ibd take boston scientific be work catch medtronic edward lifescience strategic acquisition read sector leader next month medtronic have number launch help boost growth company see strong growth emerge market segment make total sale have see double digit growth recent quarters believe medtronic sustain double digit growth market drive market development channel optimization public private partnership matson say saudi arabia see return growth soon rbc novarro expect medtronic continue gain share implantable cardioverter defibrillator market device be used manage tachycardia expect transcatheter aortic valve replacement drug coat balloon perform well novarro call line slightly better first second quarter metric edward expect medtronic launch corevalve evolut drive growth also edward sapien xt device be transcatheter aortic valve implant patient harden heart valf unable undergo open heart surgery novarro recommend own edward stock go second half expectation market growth evercore kumar note edward stock be growth stock therefore volatile nature lower investor expectation believe edward share be poise catch trade offer asymmetric risk reward current level write research report see upside current stock level kumar be previously sideline edward stock competition boston scientific international market boston pull lotus valve market late february give edward first break month still company be likely patent standoff first half related medtronic do heart valve study rival reap benefitsboston scientific win patent battle vs edward german courtboston topple heart valve bug wo boost edward medtronic
6,ZBH,fake news year be virtually impossible get reporter interested legitimate obama administration scandal now be so eager run scandal story incoming trump administration be make story major news outlet demonstrate first be new york time hit piece trump pick energy secretary rick perry claim day perry accept job know almost nothing fact key function energy department be stewardship nation nuclear arsenal story spread wildfire journalist fall other tweet clever perry put down be time alarm claim base nothing more twisted interpretation single quote person michael mckenna republican energy lobbyist be canned trump transition team perry be picked mckenna have say time misinterpret say apparently time reporter editor be so eager get bogus story perry nomination hearing start didn read statement perry issue day accept nomination look forward engage conversation development stewardship regulation energy resource safeguard nuclear arsenal promote american energy policy create job put america first emphasis add do sound someone didn know part energy department portfolio story be so egregiously wrong even liberal new york magazine take time task spread false rumor just day cnn run hit piece rep tom price trump pick head health human service department supposedly engage insider trading last year bombshell story publish tuesday title first cnn trump pick invest company then introduce bill help say price have buy much worth share zimmer biomet zbh company make knee hip replacement then story go introduce hip act have delay obamacare regulation implement hurt zimmer biomet other device maker cnn reporter manu raju assert raise new concern ethic expert price have inappropriately used information purchasing share company look timeline raise significant question cnn erin burnett say story sen charle schumer respond cnn report call delay price confirmation hearing congressional ethic office do thorough investigation not sort self deal hasn go washington peter schweizer book throw be full such example include lucrative stock trade nancy pelosi john kerry other prominent democrat schweizer book lead stock act try combat insider trading lawmaker only significant question cnn story price raise have do cnn credibility news source worth note outset hip act have chance make law fact didn even make committee have be promptly vetoed have manage make president obama desk anyone involved legislation time have know include price congressman introduce bill time know aren go anywhere rest cnn story fall apart just cursory look fact first price didn buy share portfolio be manage morgan stanley design account investment strategy direct trade part routine rebalance price account early morgan stanley buy share zimmer biomet worth grand total price net worth be order timing transaction doesn implicate price way morgan stanley buy share mid march didn tell price trade other make rebalance april be nearly week price introduce hip act everyone know be dead letter have impact zimmer biomet stock price anyway other word be story here much less scandal fact cnn pretend be say nothing price ethic do however say plenty blatant partisan bias today independent press note be update include new york time story rick perry related fake news trump do not mock disabled reporter other lie leftthe washington post take trump bias new levelmedium misreport gallup poll result trump ability
7,ZBH,stock bleed again thursday loss be weight more heavily technology certain medical sector meanwhile long term government bond price rise side pond send yield year bond year bond yield edge back accord tradeweb british judge rule only parliament formally begin process country exit eu commodity fall lead slide west texas intermediate crude oil future barrel gold edge lower comex silver slide nasdaq fall touch drop nasdaq composite apple aapl fall slightly more dip back cup handle point first time towering volume sell signal watch see stock hold close proper entry begin fresh rebound market still pressured uptrend distribution still heavy recently key index not surprise other growth stock have joined apple stumbling back prime entry point especially field medical device abiom abmd have fall nearly just week heart pump innovator be back cup handle entry also medical sector artificial joint replacement maker zimmer biomet zbh edge higher only have fall more week high now hover roughly entry long bottom base zimmer earlier week plummet report rise earning share marked second quarter row decelerate profit growth sale rise just warsaw ind firm notch gain prior quarters thank merger biomet complete june drop generic drug medical service drug wholesale biotech gaming stock pace decline dow jone industrial lose activision blizzard atvi be market leader have recently drift back prior buy point regular session stock gain return back recent flat base buy point stock be also try reclaim day move average wall street see video game creator quarterly profit double cent share pickup revenue close activision meet consensus estimate exceed prior outlook gaap earning vault cent crush wall street view nearly company report monthly active user logged more hour play month period ceo bobby kotick note news release newest futuristic battle game franchise overwatch have incredible player engagement have top player month activision also forecast net revenue vs year stock initially fall nearly extend hour trading later rebound nearly break even elsewhere stock market today solar firm get trample former huge market winner first solar fslr report plunge third quarter sale worst year year decline more year earning beat wall street view yet still drop share stock tank notch lowest level april starbucks sbux gain more hour follow news coffeehouse chain post rise gaap earning cent share include cent stem extra week operation september end fourth quarter revenue grow company open net new store raise total country stock have be struggle gapping lower april lose support day move average starbucks hold barely lukewarm composite rating scale ibd stock checkup related apple retreat back price be time buy apple lose buy point microsoft bofa edge job tap investing action planwhy bottom base help growth value investor make moneygeneric drug maker crash report doj plan collusion handle activision blizzard share buy sell hold activision show robust result be holiday guidance light
8,ZBH,medical device company composite rating top stock be build recent gain strong quarters thursday morning cardiac device giant boston scientific bsx hit year high early trading thursday sale growth guidance beat expectation make weaker expect margin boston scientific sale grow year earlier quarter strongest growth nearly decade more analyst consensus also add full year sale guidance imply increase last year boston scientific outperformed board beating revenue estimate business drive organic sale growth acceleration business geography cardiology emerge market organic sale growth be stable vs write leerink analyst danielle antalffy research note note gross margin be weaker expect be ep cent share be merely line view top line beat company do add penny full year ep guidance however see promise margin expansion boston scientific stock hold excellent composite rating hit early trading stock market today highest point february close thursday share be ibd take boston scientific strong financial stock performance have put ibd big cap list growth stock too big volatility associate smaller growth stock medical device stock zimmer biomet zbh hit time high thursday also top expectation raise guidance gross margin miss expectation also company have manage trim tax bill say foreign exchange headwind be softer initially fear strong sale growth drive hike full year earning guidance zimmer sale have grow upward last quarters thank acquisition pro basis guidance imply growth year zimmer stock peaked early trading thursday end day composite rating be finally heart pump maker abiom abmd also report strong quarter marked return profit growth negative quarters abiom stock nonetheless dip analyst antalffy warn be case note market open quarterly performance drive share outperformance today fundamental perspective note investor expectation go result be high mitigate potential outperformance write abiom share finished day composite rating stock hit time high last week
9,ZBH,several top rate growth stock have be move higher recent day thank strong earning report come week see more same latest week featured stock space be buy point ahead earning deliver nice option win intuitive surgical isrg soar earning beat slight acceleration
10,ZBH,day stock market didn have much effect thursday new high list several name score new high ahead upcoming earning report commvault system cvlt provider datum information management software picked strong volume close just entry result be due july open international
11,ZBH,ishare medical device etf ihi be year top etf leader ride best part mixed health care sector year medical sector have diverged industry fare much better other biotechs other drugmaker be roughly ibd medical product equipment industry group be only diversify medical company be do quite well health care much outperformance medical device owe superior result top manufacturer innovation have play key role ignite industry leader stock etf medtronic mdt be largest hold more portfolio share have climb much buy point april stock have perform decently fact earning have be basically flat quarters outlook be improve analyst expect profit rise fiscal year end april next year investor day june medtronic forecast mid single digit revenue growth develop product pipeline draw diversify market edward lifescience ew be stock have shoulder etf advance share be time high main move year be april company announce sapien transcatheter aortic valve replacement be show reduce death heart attack patient moderate risk open heart surgery share soar news medtronic corevalve compete edward heart valve replacement patient not able have open heart surgery analyst canaccord genuity remain bullish stock follow earning report say dominate market transcatheter aortic valve replacement show potential market expansion share stryker syk have broadest range orthopedic product peer have climb much year fall sharply july earning report be clear explanation slide other softness emerge market other key contributor ishare medical device be thermo fisher scientific tmo make equipment medical research zimmer biomet zbh just post strongest quarter sale growth nearly decade becton dickinson bdx have be trend higher fall sharply thursday cut full year sale forecast cite currency headwind etf be extend april pullback day move average june remain buy point week tight pattern form july ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
12,ZBH,be huge week earning apple aapl facebook fb alphabet googl amazon amzn beat forecast mcdonald mcd ford motor indicated weakness demand tech step include verizon vz deal buy yahoo yhoo core asset economy be grow lot slower expect oil price be near barrel nasdaq composite rise best level early december fuel strong earning apple facebook alphabet amazon hit new record high friday close week fractionally dow jone industrial average fall also snap week uptrend weaker oil price earning report hit energy sector federal reserve statement term economic risk have diminish seem have little impact investor iphone maker earn share year year sale be apple second straight decline earning revenue iphone sale be still better expect apple current quarter revenue target be midpoint wall street consensus iphone be expect be release mid september apple stock rise week just retake day line amazon ep shatter estimate revenue rise amazon web service continue boom revenue guidance also be strong operate income be light amazon stock rise week hit record intraday friday ibd take amazon be leaderboard stock hit new high growth boom only rate ibd retail internet group see go ibd stock checkup facebook report revenue maintain streak double digit growth go back more year ep jump cent shatter consensus cent be fourth straight quarter accelerate earning growth facebook stock rise hit record high still range buy point twitter twtr report ep top view revenue fall short revenue guidance also miss estimate twitter stock fall close week day line bounce back miss alphabet report ep revenue blow past expectation google parent earning item rise share total revenue climb google size still deliver growth say mark mahaney analyst rbc capital be now straight quarter ish year year revenue growth do mention acceleration say report alphabet stock rise close just entry point rise high ford motor send signal long auto industry bull market be auto sale stall higher incentive hit profit margin automaker earning share revenue rise ep growth be weakest quarters sale growth be slimmest quarters ford cite downside risk global growth offer further evidence slow auto part maker lear lea miss sale warn revenue gentherm thrm earning miss volkswagen vlkay sale edge net profit plunge vs year early struggle recover emission test cheating scandal involve diesel engine model ford stock fall federal reserve left interest rate unchanged day policy meeting expect policymaker say term economic risk have diminish suggest baby step raise rate analyst say open door slightly september rate increase fed meeting weak gdp datum investor push back expectation next hike next month economy rise annual rate less half wall street expect downwardly revise pace consumer spending be very strong climb residential investment fall even separate report show new exist home sale hit multiyear high business investment contract third straight quarter oil price fall back barrel corporate spending remain weak go forward crude oil future tumble barrel hit month lows crude tumble july crude gasoline supply rise again accord energy information administration also report higher production number oil rig operation rise fifth straight week suggest further production gain glut gasoline refine product suggest less refinery demand crude ahead meanwhile exxon mobil xom chevron cvx conocophillip cop report weaker expect result mobileye mbly report ep jump cent revenue grow top view maker driver assistance system say relationship tesla motor tsla be end news send mobileye tuesday stock pare loss week tesla rise boee ba report first quarterly loss year due various charge wasn deep fear free cash flow be better expect big jet delivery northrop grumman noc report modest earning sale growth top view weaker tech service revenue hurt margin raytheon rtn beat view raise profit guidance general dynamic gd top earning raise ep guidance revenue miss mcdonald earn share beating analyst expectation total revenue fall vs year earlier analyst have expect global same store sale exclude currency effect rise vs estimate same store sale rise just management say be not immune consumer unease be finance election general unsettled world have hurt other restaurant quarter share fall week tumble day day move average buy point stifel nicolaus downgrade large number restaurant stock jeffery predict recession hit sector top rate texas roadhouse txrh report earning come week fall wednesday steakhouse chain find support day line close week unite technology utx maker pratt whitney brand aircraft engine otis elevator other product report second quarter earning share revenue beat estimate raise ep estimate stock hit year high buy point caterpillar cat ep revenue fall mining construction equipment giant deal energy mining downturn stock hit roughly year high rise entry point chemical giant dupont dd be merge dow chemical dow crushed earning estimate be light revenue share rise highest point mid december trigger buy point meanwhile mmm make tape adhesive medical supply other product also report higher ep lower revenue beating estimate share fall analog device adi agree buy linear technology lltc cash stock deal worth create microchip industry giant deal be expect close first half meanwhile oracle orcl say buy cloud service provider netsuite deal oracle larry ellison be lead shareholder netsuite meanwhile citrix system ctxs merge go meeting unit logmein logm citrix be already plan spin go meeting verizon communication acquire struggle core asset yahoo nearly include stock compensation cost massive execution challenge ahead yahoo acquisition demonstrate verizon recognize own limitation consumer brand say research firm diffusion group verizon report revenue miss view line ep add fewer wireless postpaid phone subscriber expect mobile tmus add postpaid phone subscriber top sprint verizon lose postpaid phone subscriber mobile earning fall still beat expectation revenue rise nearly tmus revenue growth continue significantly outpace peer say matthew niknam deutsche bank analyst report armour ua meet top line bottom line expectation report share earning penny prior year revenue growth nike nke rival announce several assertive plan include takeover fao schwarz space manhattan well partnership kohl kss share tumble week amgen amgn beat raise stock slip growth continue be drive price increase rather volume celgene celg meanwhile jump only third growth be price drive make hit earlier week drug revlimid fail lymphoma trial abbvie abbv merck mrk alexion pharmaceutical alxn also rise solid report astrazeneca azn be biggest winner stock wise jump thursday rumor swiss pharma novartis nvs be think acquire biggest loser be gilead science gild trim guidance hepatitis franchise continue decline meanwhile top rate medical device company edward lifescience ew orthopedic giant zimmer biomet zbh hit new high beating estimate raise guidance big cap stalwart boston scientific bsx hit year high report strongest quarter sale growth nearly decade
13,ZBH,bullish gain stock market friday result boatload breakout new high late session new high screen yielded company most name still buy range martin marietta mlm extend gain recent low volume flat base entry share rise small cap exlservice ticker
14,ZBH,here investing action plan need know investor come week earning season kick report alcoa aa jpmorgan chase jpm citigroup amazon amzn be hold second annual amazon prime day boee ba rival airbus eadsy compete deal farnborough lockheed martin lmt
15,ZBH,major average end mixed thursday ahead friday highly anticipate job report exxon mobil xom chevron cvx lag dow oil hit month low costco cost be top gainer nasdaq report strong june sale nasdaq outperformed rise dow jone industrial average ease preliminary datum show volume nyse nasdaq come slightly lower wednesday level west texas intermediate crude oil august delivery tumble nearly barrel government datum show crude stock fall less expect economic news private employer add job june accord adp datum come ahead friday job report economist expect nonfarm payroll rise consensus estimate range be quite wide economy create paltry job several stock be set basis try break market like job report retailer lowe low add work flat base buy point guidewire software gwre rise carve cup handle base entry zimmer biomet zbh picked form flat base buy point couple merger announcement make headline stock market today french yogurt maker danone announce plan buy ibd component whitewave food wwav share whitewave soar meanwhile share avg technology avg vault news be acquire privately hold virus software maker several other ibd member turn strong performance silicon motion technology simo jump company lift revenue guidance chip designer have be standout performer base march silicon motion be several top performer ibd chip designer industry group see other leader be ibd stock checkup elsewhere leaderboard name veeva system veev jump new high rise strong volume
16,ZBH,stock show more tentative action tuesday major index fall fourth consecutive session nasdaq slip lose less dow jone industrial average sag market wary mood dow jone utility average benefit rise volume stock market today run modestly higher vs previous session accord preliminary datum session lose streak nasdaq volume have be average day ibd industry group finance banking stock take hard hit tuesday auto part niche be top gainer group ride higher mainly back stock motorcar part america mpaa advanced wild action stock fall open then rebound peak catalyst be earning report involved miss earning revenue be beat miss depend estimate used ibd dave buster entertainment play leap almost twice usual volume restaurant operator be only ibd stock combine strong price gain strong volume meanwhile zimmer biomet zbh gap triple volume zimmer be only ibd drop fast trade loom vote leave european union have be blame much market recent trouble however gamble house continue see exit unlikely poll bettor say vote approach many late decider go route perceive safest stay eu fit description
17,ZBH,stock loss intensified tuesday brexit fear internet giant amazon com amzn facebook fb try buck tide nasdaq briefly turn positive fall so do dow jone industrial average major average have fall day move average small cap fared slightly better russell fall volume be tracking lower board loser lead winner nyse nasdaq wall street have be follow foreign stock have be slide worry vote exit european union later month europe cac be paris frankfurt dax be london ftse shed chipotle grill cmg slide more active trading lowest level july deutsche bank cut chipotle grill price target say note publish monday customer be lose good follow coli outbreak last year facebook bounce day short seller citron research say company be lose relevance social medium stock be rise microsoft msft agree acquire linkedin lnkd monday deal amazon rise high be now amazon be slightly buy point volume be average rank stock highest average trading nxp semiconductor nxpi rise high early fall chip company say late monday sell standard product business chinese investor beij jianguang asset management wise road capital nxp semiconductor share have be form saucer handle base buy point zimmer biomet zbh gap day move average lose nearly heavy trading medical product company price share offer share zimmer biomet close monday
18,ZBH,spinal product stock be move tuesday ldr hold ldrh agree be acquire device giant zimmer biomet zbh come nuvasive nuva make smaller buyout late monday ldr stock soar stock market today roughly price zimmer agree pay deal amount total zimmer say buy ldr technology cervical disc replacement call fastest grow segment spine industry ldr technology be design make spinal surgery simpler less invasive ldr founder be still lose money zimmer say have impact ep year next rbc capital market analyst glenn novarro say buyout boost zimmer profile fragmented spine industry combine portfolio raise zimmer spine market share putt company striking distance strkyer syk nuvasive hold market respectively novarro write research note currently ldr rep cover approximately spine surgeon utilize combine sale force zimmer be able quickly expand coverage footprint mobi mivo suite product locally abroad zimmer stock touch record high close stock rank ibd list top perform stock zimmer stock have highest possible composite rating learn more ibd stock checkup nuvasive stock jump briefly time high early trading tuesday finished close late monday company say agree pay cash biotronic neuronetwork make system monitor patient nervous system surgery nuvasive say buyout expand clinical service arm double footprint supplement surgical product offer spine solution surgeon spine startup globus medical gmed rise unusually high volume tuesday perhaps buoy further buyout possibility space leerink analyst richard newitter also note industry giant medtronic mdt say analyst day monday expect growth pick spine business few year lag see positive smaller player still believe medtronic recent spine growth improvement stem more underlie market stabilization improvement less bad infuse erosion vs enhance competitive position vs smaller player thus have doubt company become sustainably more effective fend market share loss player such nuvasive globus medical newitter write research note newitter write prefer nuvasive globus stock ibd rating system agree nuvasive have composite rating globus have cr
19,ZBH,first republic bank frc be number bank break basis wednesday likely anticipation federal reserve raise interest rate june meeting higher rate widen spread low rate bank pay depositor higher rate charge lender increase bank profit many most
20,ZBH,medical sector bury slumping drugmaker still have few big capitalization stock have be shine biotechs be more year ethical drug maker be more generic drug company nearly worry pricing power have contribute bad sentiment pharmaceutical other segment medical sector be fare much
21,ZBH,nasdaq take stab tuesday best gain more month stock market approach day last hour trade blue chip lag gain dow industrial step nasdaq small cap russell lead pop respectively volume be higher nyse slightly lower nasdaq compare previous session technical be improve stock market nasdaq retook day day line tuesday also reclaim day line climb day line march recently nasdaq day line crossed back day line be positive development dow industrial be almost exception tuesday afternoon stock rise include visa add biggest percentage gain early march visa volume be average tuesday boee ba be dow only loser strong volume be visa stock overdrawn selling be stock ready charge higher see ibd stock checkup top rate stock featured many breakout new high stock breaking include turbotax provider intuit intu chip designer ceva ceva joint replacement maker zimmer biomet zbh telecom software developer broadsoft bsft water heater maker aos financial datum analytic provider global spgi global be formerly know mcgraw hill financial new high include designer organic lead device universal display oled chip designer nvidia nvda software developer cadence design system cdns broadridge financial solution br chip designer maxlinear mxl economic report release tuesday offer grist bear bull alike bear richmond federal reserve manufacturing index be weaker expect wall street have project read figure come sign contraction april read be manufacturing weakness have be concern recent month manufacturing account gdp bull new home sale april trounce expectation street consensus estimate be economy post stunning beat highest level more year figure easily top entire range estimate run low high homebuilder stock rise response gain mostly range many stock remain far high toll brother tol jump more tuesday strong quarterly report stock be still august peak homebuilder stock have better look chart most group horton dhi be high nvr nvr be only high
22,ZBH,load player buyer watch monday action mostly sideline major average get late lift pare loss close trim intraday loss nasdaq ibd also give dow jone industrial average ease transport lag dow jone transportation index
23,ZBH,top rate stock remain buy point recent attempt zimmer biomet holding zbh clear buy point long cup handle intraday wednesday reverse close volume be well average maker orthopedic dental reconstructive implant carry composite rating put
24,ZBH,group medical product company have be trading sideway month perhaps base long advance stock group look ready assume leadership market find way sustain rally group be rank monday week
25,ZBH,way build watch list be look stock generally meet stock pick criterium legendary investor ibd founder william neil berkshire hathaway brkb ceo warren buffett list highlight stock make neil buffett screen find marketsmith be base currently potential buy zone keep mind company be schedule report earning soon cause stock swing datum william neil warren buffett screen create generate marketsmith remember research stock further make investing decision include review company fundamental ibd stock checkup overall market condition big picture excerpt ibdextra newsletter
26,ZBH,medical industry have lot prove upcoming earning season last round earning guidance didn do much reassure investor be already nervous other reason however major stock sector have be hit new high lately especially hardware side group here be such company report earning week johnson johnson jnj take traditional place head line report earning early tuesday first big drug company report cycle growth be expect be modest due gigantic size foreign exchange headwind have be drag global company earning year analyst poll thomson reuter estimate revenue rise year earlier quarter earning be estimate share muted growth johnson johnson stock hit record high trading friday close day fraction have maintain ibd relative strength rating last week mood wall street go quarter seem bullish late thursday rbc capital market analyst glenn novarro raise estimate base read drug prescription foreign exchange trend im im script trend several key drug suggest strong pharma quarter year year ex fx olysio novarro write olysio be hepatitis treatment additionally analysis currency movement begin year suggest negative fx impact full year result be less initially expect novarro note likely topic conversation conference call be month fda approval pfizer pfe inflectra biosimilar version blockbuster immunology drug remicade robotic surgery specialist intuitive surgical isrg be due report close tuesday analyst estimate earning rise last year share sale intuitive surgical have also be top perform stock lately company have be make comeback financially rollout da vinci xi surgical system improve procedure growth intuitive surgical stock hit new high wednesday more year boast excellent ibd composite rating close friday head key question investor be stock be baking too much optimism be start new product cycle evercore isi analyst vijay kumar write email client friday expect procedure volume be healthy growth general surgery lead way extra day leap year also help similar concern optimistic market seem be dog orthopedic giant stryker syk be due report close wednesday stock have also be roll wednesday hit new high be wound last year share close friday stryker stock keep climb last week even robert baird downgrade neutral barclay resume coverage underweight latter write stryker valuation appear be full go face more competition rejuvenate zimmer biomet zbh analyst cover stryker estimate sale rise quarter earning share
27,ZBH,artificial intelligence now firmly entrench many hospital operate room field robotic surgery be start get competitive giant company alphabet googl johnson johnson jnj medtronic mdt be training sight intuitive surgical isrg king robotic surgery company analyst say boom medical technology segment have lot room run robotic surgery be area grow billion dollar more machine be used treat patient intuitive command space annual sale signature da vinci robotic surgeon however be limit type procedure handle multus limb da vinci be used variety procedure include cardiac colorectal gynecological head neck thoracic urologic surgery only long re minimally invasive big market be be still unclear yet analyst agree potential have yet be tap so more player be move quickly get newsletter deliver inbox more info product service privacy policy term use think investor need understand robotic ai artificial intelligence revolution be happen touch sector economy say jeremie capron director research manage partner robo global index advisory firm specialize robotic industry investment be technological revolution investor afford miss analyst say march auris health become first company formidable threat intuitive catheter base monarch platform gain approval intuitive counterpunch seek approval flexible catheter similar auris device likely year rbc analyst brandon henry say recent report meanwhile other be work area intuitive surgical doesn have foothold nephew snn have robotic assistant knee replacement stryker syk have robotic joint replacement system mazor robotic mzor zimmer biomet zbh have robotic offering brain spinal surgery mazor alone see sale just system player have long way go take intuitive surgical throne intuitive have market cap today worth nearly capron call intuitive amazing stock think investment community have be scratch head try figure impact new entrant intuitive surgical tell investor business daily feel pretty relax size be big enough small player come share medical tech company have be relatively insulate wo frustrate biotech pharmaceutical stock late stock medical equipment maker such intuitive mazor have collectively spiked year date intuitive blowout quarter april help spur excitement evercore analyst vijay kumar say recent note client recent investor day medtronic be help drive frenzy robotic surgery be topic currently medtech blowout quarter intuitive surgical hint pace manual robotic transition be pick kumar say topic competition elicit various response investor intuitive surgical stock be year climb kumar expect intuitive surgical competition become more apparent next month intuitive da vinci surgical system now boast patient count da vinci system be also move deeper hernias be see early stage adoption bariatric surgery perform induce weight loss myriam curet executive vice president chief medical officer intuitive note email ibd estimate prostatectomy be perform robotic assist surgery same be true malignant hysterectomy general surgery be fastest grow specialty be still early stage adoption procedure such ventral inguinal hernia repair colorectal bariatric surgery say believe be substantial opportunity expand robotic usage category be develop additional tool technology do so year intuitive guide first quarter earning conference call growth number procedure perform system year follow many consider strong fourth quarter recur revenue include instrument accessory da vinci system grow recur revenue represent sale pie still even intuitive surgical see early innings expect robotic surgery present huge total addressable market number da vinci procedure perform year grow nearly other robotic surgery company intuitive closest competitor auris doesn trade publicly recently be stealth mode kumar say medical technology company sign agreement division agreement come month auris monarch system grab approval monarch be flexible catheter surgeon thread patient mouth lung remote control approval investor believe credible competitor intuitive be year away kumar say monarch get approval month ahead view intuitive surgical plan seek approval own flexible catheter later year auris say monarch first target be lung cancer expert estimate half lung biopsy be perform year surgeon also use flexible catheter urinary tract procedure number roughly procedure year intuitive isn sweat competition auris chief executive interestingly be frederic moll founder intuitive surgical intuitive current ceo gary guthart joined medical technology firm take ceo have build technology make decision architecture base first principle not look shoulder other person be do really engage customer deeply understand clinical need guthart say recent earning call rbc henry note auris monarch have larger catheter intuitive allow camera intuitive see benefit smaller catheter move deeper lung henry write recent report allow surgeon potentially use remove diseased tissue meanwhile have team google company call verb surgical analyst be unsure system team be create do expect enter robotic surgery market same time medtronic be partner mazor medtronic also expect own robotic surgery system launch not unreasonable suggest intuitive keep market evercore kumar tell ibd new robotic surgery company have differentiate have straightforward too product say investor have put pretty punchy marketable valuation intuitive surgical re still early stage robotic conversation add market be big enough sustain multiple player company mazor zimmer biomet make system call rosa come have system surgeon use brain spinal procedure other mazor ceo ori hadomi say sizing opportunity robotic surgery company be difficult surgeon use mazor system spinal surgery company renaissance system perform spinal brain surgery cost disposable instrument material comprise mazor revenue hadomi tell ibd surgery perform mazor list price be term disposable item estimate half procedure generate stakeholder expect spine procedure grow rapidly person be be more more active say meaning suffer more injury require surgery more often procedure become less invasive safer procedure become more patient be willing interested be treat be operated benefit robotic surgery be plentiful hadomi say revision surgery surgery correct mistake tweak prior surgery be significantly lower robot assist precision robot help curb potential error say last october mazor unveil result patient study find fivefold reduction complication surgery perform mazor robotic surgery technology notably be also sevenfold reduction revision surgery compare freehand lumbar fusion surgery doubt patient perspective not consider go surgery robot know chance go revision surgery be time higher say revision surgery be also costly hospital face reimbursement hurdle agree robotic surgery win replace human surgeon hadomi liken system other toolbox surgeon be simply medical technology tool make operate easier surgeon safer patient say benefit be also grow investor say robo global capron really exciting be fact be inflection point technology enable robotic surgery price point be attractive say now lot action medtronic see confirmation be substantial addressable market related look best stock buy watch start herecan crispr small biotechs cure disease amazon vs walmart locking horn battle retail futurechart read basic buy point mark time real marijuana industry overtake beer legalization spur innovation
28,ZBH,zimmer biomet holding zbh monday plunge monday month low medical supplier lower full year forecast weak third quarter earning report warsaw ind base maker orthopedic device say now see diluted earning share previous forecast adjust earning estimate be cut range share bring upper end spread share end day tumble zimmer violent stock reaction parallel other medical supplier have report recent day edward lifescience ew plunge more wednesday earning disappoint abiom abmd stumble more day last week boston scientific bsx slip few point report earning stryker syk see healthy uptick report gain more zimmer expect revenue growth be well exclude company acquisition ldr hold growth be expect run instead previous forecast company say net income quarter be adjust earning be share line analyst estimate revenue fall short forecast analyst survey thomson reuter expect zimmer expect full year earning range share revenue range analyst be predict earning share sale
29,ZBH,stock index hold modest gain afternoon trading amazon com amzn get love analyst utility lead market nasdaq climb most important component bounce bit amazon com be batter friday earning rise nearly double usual volume nomura set price target amazon com also thestreet com report baird give bullish view stock reiterate outperform rating price target addition moody issue report say retailer benefit healthy holiday sale growth disappointing season commerce sale remain fastest grow segment retail industry moody note add dow jone industrial average inched fraction nike nke be more big volume bank america downgrade athletic apparel brand underperform neutral volume be tracking lower board utility be strongest day trading sector have be mend early part october ibd utility industry group today make best gain bounce water utility be gas electric diversify be specific trigger today rally appear be snap back move period difference yield utility bond get stretched say john bartlett utility analyst reaf asset management energy sector be weakest accounting worst perform industry group exploration oil field service drill pipeline group be crude oil fall nearly early afternoon trading chevron cvx be more goldman sachs upgrade stock conviction buy list neutral chevron be form base buy point baker hughe bhi reversed lower wipe gain baker hughe announce today combine operation general electric ge oil gas operation ge share be sell off health care stock continue zimmer biomet holding zbh plunge huge volume touch lowest level month orthopedic product company lower full year profit forecast share earlier forecast zimmer biomet meet estimate adjust ep share sale increase related fail halliburton deal baker hughe merge operation geoctober auto sale expect gm ford other
30,ZBH,load player mutual fund manager other large investor take interest medical product maker zimmer biomet zbh have earn spot ibd list top growth stock industry peer align technology algn edward lifescience ew tuesday stock fall day move average heavy volume
31,ZBH,stock index battle overcome turbulence midday wednesday slew issue suffer bearish gap move open nasdaq gap much then backfill gap loss early dunk take composite back day line find support bounce be flat dow jone industrial average advanced volume stock market today be run modestly higher major exchange compare previous session unusually high number blue chip stock suffer gap down open gap occur stock open stay lowest price previous day range be comprise biggest blue chip dozen stock gap be unusual conservative stock gap down include simon property group spg apple aapl home improvement chain lowe low early gap down reversed fill part gap session continue ibd take gap down make individual investor think twice buy stock northrop grumman gap buy zone wednesday case negative reaction seem bit excessive dow transport member southwest airline luv gap torrid volume earning top consensus estimate revenue fall shy expectation guidance be weak company say expect unit revenue decline strong market have shrug negative focuse earning beat least contain damage market be clearly pressure growth stock also suffer gap down medical device maker edward lifescience ew be online food delivery service provider grubhub grub pizza chain papa john pzza surgical product firm zimmer biomet zbh internet content company line ln chipotle grill cmg relatedchange focus help coca cola beat earning estimateswhy do wall street clinton
32,ZBH,load player stock market start week solid foot volume be light due columbus day holiday oil gas stock do heavy lift oil price jump again nasdaq composite gap rise dow jone industrial average rise close lower
33,ZBH,columbus day kick week offer investor chance new buy opportunity top rate stock facebook fb broadcom avgo zimmer biomet zbh list highlight additional stock have horizon facebook broadsoft bsft other ibd stock have recently pause clear recent buy point gain traction
34,ZBH,here investing action plan thursday need know investor come day lull just earning season begin next week make quiet calendar be several stock near buy point include broadcom avgo thermo fisher tmo stryker syk deutsche bank db also be address major
35,ZBH,good news bad news come latest ibd screen top perform growth stock good news be several name be hit high outperform broad market bad news be many be too far extend past proper buy point be actionable be exception ellie mae elli
36,ZBH,global market starve growth lead manager justin kelly think mainstay large cap growth fund mlaax be feast shark school tasty fish lose more twice much ground first quarter average large cap growth rival track morningstar inc fund double peer group gain so far quarter be ahead vs peer mutual fund go thursday so fund sudden burst speed market have tilt back type stock favore fund include stock unitedhealth group unh be year lead manager justin kelly think party growth stock be still ramp growth stock underperform year vs call safety stock kelly say safety stock do best year bond be decline yield be utility staple telecom reit do well first half year june fund have be tear fund focus stock grow faster broad market current global market growth overall be slow stock manage generate average growth be greater demand kelly say happen growth stock do better value fund rip key fund maneuver various market phase adjust allocation type growth stock manager seek bucket contain stock fund see long term sustainable earning grower second bucket contain quality cyclical grower third hold stock newer industry rapid growth sustainable grower have competitive advantage let grow year year unitedhealth group be example revenue provider health care coverage benefit service have grow double digit pace quarters row broadcom avgo be fund cyclical have radio frequency filter be highly desirable best market allow mobile phone jump frequency kelly say give pricing power few other vendor semiconductor industry have broadcom filter kelly add enable phone work network different country user move cell tower facebook fb be bucket stock newer industry rapid growth top hold june rapid growth come market share gain advertising return investment advertiser be better get other platform television print kelly say more advertiser shift dollar higher facebook think growth continue year intuitive surgical isrg be also rapid growth bucket intuitive robot system be start catch new surgical market especially hernia case kelly say have become widely used prostatectomy hysterectomy growth have lag heyday estimate earning growth be street perhaps current slow growth economic environment manager think best prospect be company fast steady earning sale growth see best opportunity newer faster grow company kelly say also consistent growth be substantially overweight newer faster grow company consistent grower be underweight cyclical still manager clark patrick burton also run fund don hibernate market tilt away strategy take advantage broader pullback market spring kelly say fund start position intuitive surgical also fund increase stake unitedhealth top hold be take market share medicare advantage medicaid market say steve hamill health care analyst capital fund subadvisor optum health service business have be tremendous growth business hamill say generate unitedhealth earning other holding activision blizzard atvi earning share jump past quarters company be shift online gaming away reliance console base video game boost margin kelly say next growth come sport turn video gaming sport spectator such person go madison square garden watch other gamer say zimmer biomet zbh be newcomer portfolio fund begin current stake spring thesis here be be steady grower hamill say re lead company orthopedic implant related surgical category fundamental slide merger zimmer biomet close june due redundant sale force other inefficiency hamill say now company have cut cost surgeon zimmer biomet product hamill add earlier year many wall street analyst expect company continue lose share especially hip knee market think grow least fast market hamill say think company growth be even better spine trauma market revenue growth margin expansion be key driver add fund institutional share mlaix carry load expense ratio minimum investment be meet plan brokerage level related john roth equal top perform fidelity new insight fundjanus manager bet proven champ comer calculate risk hot hodge mutual fund shine several lead stock holding climbwhy winning mfs fund prefer stock durable growth fastest growth
37,ZBH,call face card big cap company deliver revenue growth better most recent quarter be growth come acquisition organic new product good be company squeeze earning growth strong revenue newell brand nwl formerly know newell rubbermaid make household good include
38,ZBH,dow jone industrial average try join other major index positive territory minute left go thursday session earning report remain focal point news oracle orcl strike deal acquire enterprise cloud service name netsuite share oracle add netsuite soar meanwhile buyer be leaderboard name amazon com amzn ahead earning report close amazon share rise nasdaq composite outperformed again rise add dow jone industrial average be fractionally lower briefly turn positive volume nyse nasdaq be tracking slightly lower wednesday level stock market today new york mercantile exchange west texas intermediate crude oil september delivery fall nearly barrel auto part retailer reilly automotive orly autozone azo advance auto part aap outperformed gain apiece reilly earning report be catalyst ibd facebook fb be session lows still rise company deliver solid quarter growth late wednesday ibd take facebook sell premium valuation justified huge growth recent quarters learn more earning influence stock price visit ibd learn center ibd name grubhub grub soar new week high second quarter earning sale growth accelerate nicely first quarter earning jump year earlier cent share cent view sale rise revisit flat base entry zimmer biomet zbh gap strong earning share rise stock be still buy range entry
39,ZBH,earning report fuel several big move thursday new high list quiet performance broad market fortune brand fbhs extend winning streak session rise extend reclaim week move average late wednesday ancillary housing play report earning share cent year sale
40,ZBH,july be gift brexit vote exit european union clobber market june few investor dare be optimistic behold july turn rebound month diversify stock mutual fund return average gain accord lipper inc investor bid market lack dramatic driver company forward earning expectation didn move much price person be willing pay company same earning have go say david lafferty chief market strategist natixis global asset management so movement be drive person willing pay more stock even earning didn move only be attribute earning move go forward lafferty team natixis have management expect continue outgrow europe japan foreign stock general offer better value equity so re lean more europe develop market share price already reflect expect growth say fairly positive emerge market have stomach volatility small cap growth fund lead diversified gain last month world equity fund rise july lag diversify stock mutual fund click here see list mutual fund month leadersdavid joy chief market strategist ameriprise financial also see growth outpace competition lafferty more bullish prospect corporate earning gain second half year so look world equity market only geography be overweight be joy say macro trend fuel outlook report july job increase june big jump anemic job gain retail sale consumer activity look solid joy say be rebound manufacturing gdp rise annualize rate second quarter nearly double pace click here see list mutual fund category performance create condition lead long anticipate recovery earning second half year joy say re half earning season re not great re little better expect be trading multiple time trail corporate earning only multiple forward earning disparity tell market be look road see positive earning growth maybe next year joy add team only sector overweight be technology precious metal fund rise last month top science tech fund gain health biotech fund advance attraction tech vary joy say couple theme include payment return capital dividend yield quality growth apple aapl verifone system pay be example company help consumer increase use payment joy say also apple boost share buyback program april oracle orcl say march be buy back share year cisco system csco carry dividend yield alphabet googl have show durable earning growth telecom be largely yield play say team be also overweight alternative investment lessen risk volatility also investor have wherewithal qualify want investment produce better return private equity venture capital say give liquidity time have opportunity outperform joy warn investor expect volatility run election base past election year market be true history be case again say volatility also be fed come vote number european nation hurt european union cohesion add justin kelly lead manager mainstay large cap growth mlaix say prospect outperformance be best traditionally growth oriented sector technology health care consumer discretionary tech fund have bet alphabet facebook fb microsoft msft visa alphabet base continue strong market share gain global advertising market improve cost discipline capital deployment say facebook be rapidly gain share global advertising market advertiser find return investment be much better online traditional offline medium advertising spending kelly add team like microsoft think satya nadella new management team accelerate company earning share growth profile shift business cloud visa have long duration growth opportunity move cash check electronic payment kelly say think grow average rate long time say health care hold orthopedic dental implant maker zimmer biomet zbh medical device maker boston scientific bsx have new product be accelerate growth expand operate margin say consumer discretionary sector team bet home depot hd reflect optimism housing cycle home depot be best way play re gain share expand margin grow earning attractive rate year come larry pitkowsky co manager midcap value goodhaven fund goodx like sector stock have be favor barrick gold abx edge july be year month end earning share be second quarter row growth straight stanzas decline ep price bullion have trend higher december barrick gold have trim debt year date say be track cut debt year have reduce leverage cost pitkowsky say be generate earning cash flow be many way grow intrinsic value here also like birchcliff energy share canada base oil gas explorer producer be trading rise july be year july ep have fall quarters fall faster most recent quarters click here see list new buy top mutual fundsclick here see list latest sell top mutual fund
41,ZBH,market continue rally here look notable stock be stage breakout stock market today general electric ge lowe low planet fitness plnt zimmer biomet zbh fortune brand fbhs general electric break cup base buy point rise move also put share more year high move stock have ibd composite rating due lackluster fundamental lowe have composite rating breaking flat base buy point hit new time high climb ibd member planet fitness composite rating advanced clear buy point quick turnover gym operator go public last august be hit highest level third day trade zimmer biomet be hit new high flat base buy point medical device developer earn composite rating stock relative strength line be hit new high ground fortune brand be hit new high well advanced share clear double bottom base buy point stock have composite rating well ibd take make sure check marketsmith stock list research tool include list day breakout
42,ZBH,stock market hold strong gain hour remain friday session cheer healthy june employment chart growth stock outpeformed ibd name maxlinear mxl dave buster play universal display oled lead charge nearly half ibd rise more lam research lrcx be top gainer nasdaq share rise nearly volatility last month reclaim buy point nasdaq jump add dow jone industrial average gain small cap do well russell flirted time high nasdaq approach level nasdaq volume be tracking higher thursday level stock market today nyse volume be pace be close thursday new york mercantile exchange benchmark crude oil august delivery add barrel week lose ibd name acuity brand ayi jump fail due brexit sell just new flat base entry zimmer biomet zbh clear flat base entry slow trade other breakout come like lowe low fortune brand fbhs guidewire software gwre alcoa aa kick second quarter earning season next week result due monday close rally nicely hit low january be get resistance week move average several week consolidate gain sign slack buy demand be confirm weak accumulation distribution rating
43,ZBH,second quarter earning season come focus now be perfect time see stock be potentially set then check calendar see report be list stock currently trading potential buy zone ahead company next earning release make list stock also have trade least share day average have higher composite rating meaning outperform stock term most important fundamental technical stock pick criterium tip see find more top rate stock buy point datum highly rate stock buy point create generate marketsmith remember research stock further make investing decision include review company fundamental ibd stock checkup overall market condition big picture excerpt ibdextra newsletter
44,ZBH,stock see modest gain fade head close major index huddle just just previous resistance level nasdaq dip minute left tuesday regular session rise dow jone industrial average volume stock market today be higher nasdaq lower nyse monday climb old resistance add small cushion tuesday nasdaq be linger just old resistance blue chip be mostly winner lead loser ratio dow oil close barrel chevron cvx pop higher brisk trade exxon mobil xom add nearly average volume integrate oil stock group have do well recently week integrate oil stock be industry group group be monday ranking investor com chevron have have trouble earning year basis have decline consecutive quarters street expect earning decline year rebound next year ibd thrust higher volume average zimmer biomet zbh drop first minute trade then make steady recovery loss stand less market head final hour trade zimmer biomet action be see bounce day line be buy opportunity zimmer biomet announce open buy ldr hold ldrh expand reach spine market austin base ldr do not make money score revenue
45,ZBH,stock open higher tuesday morning dramatic premarket loss drugmaker dow jone industrial average lead gain be nasdaq hold fractional gain stock motion include valeant pharmaceutical vrx alexion pharmaceutical alxn unite natural food unfi zillow group biogen biib test stock market today be volume monday gain feel good take place relatively weak trade ibd big picture monday note suggest institutional investor remain bench not bullish sign gain rise trade provide market uptrend more momentum still open just july high move level be psychologically important point watch small cap russell smallcap outperformed market monday labor department say productivity decline first quarter line expectation improvement initial estimate decrease unit labor cost rise consensus forecast change department initial estimate rise federal reserve be deck deliver april consumer credit datum et oil natural gas stock crowd top william company wmb marathon oil mro be pharmaceutical play be take beating however valeant crumble first quarter revenue top analyst view earning stop well short target management slash full year sale earning guidance far expectation alexion nose dive report late monday late stage study neuromuscular disease treatment soliris miss expect goal alexion share have be try climb right side deepen month consolidation biogen skid preliminary datum phase clinical study show multiple sclerosis treatment opicinumab miss primary endpoint trial bright spot medical picture be ldr hold ldrh spiked open zimmer biomet zbh say acquire cervical surgery product company deal value ibd stock zimmer be recreational vehicle maker thor industry tho scratch gain open elkhart ind base company report earning just estimate revenue just analyst consensus target stock end monday buy range past cup base buy point overseas market trade higher boost federal reserve chair janet yellen pushback monday expectation rate hike hong kong hang seng index take gain tokyo nikkei add europe frankfurt dax cac paris carry gain better oil price climb west texas intermediate nearly barrel europe brent crude benchmark climb close top barrel gold slip less ounce dollar rise year treasury yield lose basis point
46,ZBH,bank stock ibd clear buy point wednesday expectation federal reserve boost interest rate early next month bank share have rise week minute fed april meeting suggest policymaker raise interest rate june meeting economy continue pick higher rate
47,ZBH,couple big cap stock be set possible basis break catalyst present market get upward momentum go be zimmer biomet zbh have set long cup handle base buy point last week base correct only
48,ZBH,load player zimmer biomet zbh be close new buy zone medical product industry group rise ranking week today maker orthopedic reconstructive product have composite rating earn spot industry leader such align technology algn cambrex cbm edward
49,ZBH,stock market hold strong gain early tuesday help strength european market overnight nasdaq lead way dow jone industrial average add volume nyse nasdaq be tracking slightly higher monday level europe cac be late trading paris germany dax gain london ftse add economic news april new home sale spiked year high ibd home build group perform mostly line market news stock market today john deere add more thank bmo capital upgrade price target hike volume be run already more double usual pace stock be still more week high so not yet close potential early big mover dow include american express axp visa ibd universal display oled follow monday strong move rise china name netease nte new oriental education edu also outperformed meanwhile earning report be once again focus toll bro tol jump better expect earning revenue be fuel strong sale luxury home california toll be laggard group still deep base build mode try regain slumping day move average see leader be ibd home build group ibd stock checkup health care space zimmer biomet zbh picked heavy volume still buy range cup handle buy point market performance be impressive light weak retail report best buy bby dsw dsw slump report sluggish earning respectively
50,ZBH,year teeter totter market have pose special challenge investor manager usaa aggressive growth usaux be exception past year go wednesday fund have outperformed rival large cap growth mutual fund track morningstar inc lose less most fund have gain volatile past month only top peer fund be prime strong performance stock market strengthen quality top holding be indication aggressive growth top holding march include stock ibd composite rating higher highest comp rating be composite rating combine ibd performance rating include ep relative strength rating stock poise move higher often have high comp rating addition holding include adobe system adbe sport comp rating trading adobe be work cup handle base buy point volume have dry handle form be positive ibd leaderboard analysis stock point adobe earlier past handle entry base be successful point view stock be extend still make case right side base need more work adobe have succeed morph company let customer receive product cloud pay subscription fee be adobe buy sell take free trial ibd leaderboard today find outrevenue growth have sped past quarters fiscal second quarter end month wall street currently expect earning rise cent share extend slowdown ep gain prior quarters still vigorous profit growth facebook fb leaderboard stock be top holding have composite rating ep gain be accelerate rise past quarters earning jump cent share easily beat wall street estimate do jump revenue stock respond upbeat result gapping april clear buy point cup handle base get high ease just buy point facebook have gifted investor big return break past buy point double bottom base week end july ibd point recently electronic art ea be top new buy have comp rating video game publisher deliver better expect earning sale growth last week ep rise profit get boost ea grow digital sale make fourth quarter revenue ibd report tuesday also ea have debt last year solid return equity average annual ep growth rate past year have attract rise number fund investor typically better perform fund own share electronic art fidelity otc focpx mfs growth mfegx other holding zimmer biomet holding zbh have comp rating be so far year maker orthopedic dental reconstruction implant trauma product related surgical product have see ep rise past quarters climb span revenue grow past stanzas company beat consensus estimate ep revenue company be born last year merger zimmer holding biomet create global leader musculoskeletal health care do business more country ibd recently report last month zimmer say take cayenne medical strengthen sport medicine offering trading stock be buy point long cup handle base portfolio be run separate subadvisor capital wellington management manage fund side outperformance skews split too much usaa rebalance funnele inflow lag portion also take shareholder redemption larger portion clark patrick burton justin kelly be somewhat more aggressive style say usaa wasif latif oversee subadvisor wellington manager be paul wellington be more conscious valuation latif say subadvisor sleeve share many name have more fang stock say usaa analyst julius barne refer high flyer facebook fb amazon amzn netflix nflx google now alphabet googl jan unitedhealth group unh starbucks sbux be sleeve only go thursday unitedhealth be year have comp rating weak accumulation distribution rating be sign more recent selling buy mutual fund past week starbucks be year have so so comp rating worst possible accumulation distribution rating oracle orcl pepsico pep be name wellington sleeve only oracle be have weak composite rating accumulation distribution rating ep fall past quarters be flat frame pepsi be less composite rating accumulation distribution rating have high growth bullish market do better latif say opposite happen market be not lead growth be challenged wellington sleeve have outperformed so far year latif say
51,ZBH,be street wear dark sunglass make thing look darker be be sky truly turn threaten analyst expect earning drop revenue inch accord report bloomberg news bull be hope low expectation lead significant beat prompt market
52,ZBH,major average end sharply lower thursday market mild distribution show more least nasdaq dow jone industrial average nasdaq lose give preliminary datum show nyse nasdaq volume come higher wednesday level stock market today stock be pressured early bank japan surprisingly hold monetary policy unchanged send yen soar euro dollar also send tokyo nikkei loss home front labor department estimate gdp growth sharply growth consensus view amazon amzn headline thursday hour session big beat share surge amazon be member leaderboard portfolio investor com other hour mover include linkedin lnkd baidu bidu regular session facebook fb easily lead nasdaq advance facebook earning report late wednesday trigger handful analyst price target increase thursday morning nasdaq chip stock lag include xilinx xlnx nxp nxpi lam research lrcx analog device adi earning report also lift share paypal pypl zimmer biomet zbh stock end session lows early strength news abbott lab announce plan buy st jude medical stj cash stock deal share st jude soar abbott lose sanofi sny meanwhile strike deal acquire cancer drugmaker medivation mdvn medivation recently release positive early stage trial datum talazoparib shrink tumor ovarian cancer patient share medivation soar sanofi give medivation have be show relative strength lately biotech group several other name see leader be ibd stock checkup downside luster wear longtime leader domino dpz share crash disappointing earning
53,ZBH,medical giant johnson johnson jnj say tuesday restructure device division bid save annually end didn provide many detail press release say discuss project further report earning jan however do specify
54,ZBH,medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate
55,ZBH,say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus
56,ZBH,company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat
57,ZBH,device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter
58,ZBH,pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note
59,ZBH,single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum
60,ZBH,imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year
61,ZBH,product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus
62,ZBH,device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company
63,ZBH,also announce stock buyback plan be finance debt issuance
64,ZBH,stock open few point late morning be flat
65,ZBH,follow amy reeve twitter ibd_areeve facebook medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company also announce stock buyback plan be finance debt issuance stock open few point late morning be flat follow amy reeve twitter ibd_areeve facebook
66,ZBH,first quarter earning season be fast unfold member elite index have report financial number apr latest earning preview total earning company have increase year year basis higher revenue further whopping company have surpass earning estimate beat revenue mark however number positive revenue surprise season be lag precede year number end week company be set release result medical zack sector be expect deliver strong result medical product space have lately see slew favorable development change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment abolition taxe increase business investment have be drive growth sector so rather be interesting see major medical product company be place ahead report cycle be major factor shape release medical sectormedical product have be very profitable investment space late favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be suppose growth driver latest tax cut job act be finally sign president trump dec have finally cheer healthcare fraternity act have lower corporate tax rate earlier buoy optimism additionally senate decision postpone medical device tax be put effect jan have instilled confidence investor bill also delay so call cadillac tax tax employer insurance let take look major medical product company be set release result apr zack quantitative model stock advantageous combination solid zack rank strong buy buy hold positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filter baxter international inc bax free report first quarter result be expect show gain hospital product unit solid guidance plethora regulatory approval first quarter zack consensus estimate earning be peg cent indicate year year growth same revenue be fix reflect year year growth further predict earning beat quarter baxter have zack rank earning esp read more hospital product unit aid baxter earning see complete list today zack rank stock here baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quoteresm inc rmd free report be expect gain strong performance domestic international front third quarter fiscal revenue europe asia other market be likely register solid increase banking strong device mask performance moreover company sleep apnea patient volume have consistently witness steady growth third quarter zack consensus estimate earning be pin cent indicate year year growth same revenue be fix reflect year year growth however model resm be unlikely deliver earning beat season resm have zack rank earning esp make surprise prediction difficult read more resm repeat stable device growth earning resm inc price ep surprise resm inc price ep surprise resm inc quotestryker corporation syk free report first quarter result be expect show strong growth back orthopaedic implant sale major revenue component additionally medsurg help company generate impressive result first quarter zack consensus estimate earning be pin indicate year year growth same revenue be fix reflect year year growth quantitative model predict earning beat stryker be stock have earning esp zack rank read more core segmental growth aid stryker earning stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotezimmer biomet holding inc zbh free report first quarter result be expect show strong top line number surgical sport medicine foot ankle extremity trauma arm moreover last november company have receive several fda clearance be particularly excited approval sidus stem free shoulder system first quarter zack consensus estimate earning be pin indicate year year decline same revenue be fix reflect year year growth zimmer biomet have zack rank sell lower predictive power esp have earning esp read more aid zimmer earning supply wo zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quoteinvestor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
67,ZBH,zimmer biomet holding inc zbh free report be set report first quarter result apr market open last quarter company post earning line zack consensus estimate however zimmer biomet miss consensus mark precede quarters average be let take look thing be shape prior announcement key company be expect report strong topline number surgical sport medicine foot ankle extremity trauma arm be report period last quarter revenue be drive solid quarterly sale company surgical portfolio also upper extremity business company see solid demand comprehensive shoulder line regard note last november company have receive several fda clearance be particularly excited approval sidus stem free shoulder system expect development significantly contribute company top line first quarter zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote flip side company business have be recent past massively ail supply issue continue pricing pressure zack consensus estimate revenue reflect decline last quarter be also upbeat spine thoracic spine cmf segment be expect deliver quarter promising performance spine category zimmer biomet continue gain strong uptake mobi cervical disc also be look forward top line contribution company recent launch product avenue tlif cage vitality vital spinal fixation system unite state however be apprehensive ongoing revenue dissynergy related company spine sale force integration zimmer biomet be work resolve impact dissynergy chance term resolution be bleak zack consensus estimate spine revenue indicate decrease year quarter overall first quarter revenue be project sequentially other factor likely influence zimmer biomet first quarter result be look focuse execution zimmer biomet sale team expect global adoption rate flagship personalize knee system persona be impressive be also enthusiastic launch persona partial knee system last september knee system marked latest addition company portfolio personalize anatomically design knee implant system zack consensus estimate knee revenue register reduction last quarter hip business expect company once again demonstrate sturdy performance asia pacific region notably previous quarter company register double digit sale growth hip aforementioned geography company be anticipate produce improve quarterly sale taperloc arco system however other segment supply constraint continue limit zimmer biomet ability meet demand high growth brand zack consensus estimate knee revenue represent dip last quarter emerge market have always be significant revenue generate source zimmer biomet recent economic downturn latin america company manage drive growth operation other emerge market especially asia pacific emea europe middle east africa zone zack consensus estimate first quarter revenue emea denote improvement last quarter however zack consensus estimate revenue apac quarter be report translate fall last quarter believe macroeconomic uncertainty unfavorable currency fluctuation have be dent company sale past few quarters company have also be burden pricing wo result zimmer biomet struggle negative pricing pressure approximately absence favorable change line headwind be mirror company first quarter result here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp zimmer biomet have zack rank lower predictive power esp earning esp caution sell rate stock go earning announcement especially company be see negative estimate revision therefore combination do not suggest company be likely beat earning quarter uncover best stock buy sell re report earning esp filter stock considerhere be few medical stock worth consider right combination element beat estimate time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
68,ZBH,apr issue update research report zimmer biomet holding inc zbh free report issue macroeconomic uncertainty pricing pressure unfavorable currency fluctuation adversely impact zimmer biomet sale recent past company carry zack rank sell last month share lead musculoskeletal healthcare company have underperform broader industry mentioned headwind stock have lose versus broader industry gain be still disappoint zimmer biomet persistently decline core knee sale performance recent past primarily due slower pace supply recovery sale recapture certain key brand particularly unite state be also worry channel integration ldr go plan dissynergy associate additionally pricing pressure remain major woe estimate revision trend be also unfavorable estimate move south none opposite direction past month stock have see zack consensus estimate current year earning be revise cent downward share positive note company operational plan look promising order address several term challenge management have recently start review plan clearly define go forward strategy number key area regard company have identify several immediate opportunity improve operational execution moreover emerge market opportunity be expect reach value reconstructive trauma market also note recent global economic downturn have massively affected zimmer biomet business latin america other part emerge market especially asia pacific emea continue drive growth company fourth quarter company witness accelerate upside asia pacific business strongly benefit distributor order particularly japan china demonstrated marked improvement key picksa few better rank stock broader medical sector be athenahealth inc athn free report bio rad laboratory inc bio free report centene corporation cnc free report sporting zack rank strong buy see complete list today zack rank stock here athenahealth have expect long term growth rate current year metric be peg bio rad have expect long term growth rate same stand centene have expect long term growth rate current year metric be project zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
69,ZBH,technological progress have be constant decade make life easier currently global mantra success be adapt upgrading trend technology latest craze digital world be printing open new avenue different sphere application start automobile healthcare also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub reebok latest liquid floatride run footwear feature print lace switch bigwig porsche bugattus printing manufacturing rare complex part phenomenon have spread far wide research firm market market expect printing market grow value cagr printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr let delve detail printing have be create new opportunity medtech investor be keen putt money healthcare space longer term gain printing change medtech landscapegrow prominence innovative printing solution have lend mida touch medtech space fda well healthcare professional be fast adopt technology enhance long term patient outcome encouragingly note materialise nv mtls free report be first company receive fda approval software design printing anatomical model diagnostic use major sub industry be try utilize resource come best burgeon printing market have zero be make most trend orthopedic implant device manufacturer be switch printing technique cater rapidly grow demand customize implantable device printing manufacturer be be able develop implant customize size shape short time improve efficacy lower overall cost surgery research firm future market insight expect orthopedic implant market reach worth cagr accord report publish cision pr newswire here appreciate zimmer biomet holding inc zbh free report fda approve unite bridge fixation system quebec city base bodycad texas base web medical be lead name print implant technology space hearing aid device printing be fast take hearing aid device market be expect see cagr orbisresearch com report publish reuter printing enable manufacturer develop device base image defective ear canal sonova hold ag lead provider hearing solution have be actively used printing come next generation hearing aid device company customize titanium print hearing aid deserve mention here dental implant printing be also gain popularity dental industry allow dentist carry procedure more precision efficiency save patient excess trauma notably dental printing be process create dimensional solid dental model such implant surgical guide brace denture crown bridge research firm transparency market research expect global dental printing market see cagr reach value global leader high accuracy dental printer material envisiontech have be actively strengthen hold niche market company recently announce launch orthodontic material lmt lab day chicago stock focuswe have select company believe be well poise provide impressive long term return banking printing trend stryker corporation syk free report have be early adopter printing technology company fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation zack rank hold company have long term earning growth rate current quarter estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly zack consensus estimate increase share see complete list today zack rank strong buy stock here stryker share price movement past month have be favorable company yielded return almost better industry orthofix international ofix free report recently announce fda approval limit market launch forza xp expandable spacer system system consist print porous titanium endplate enable patient bone grow porous plate zack rank company have long term earning growth rate company have deliver positive earning surprise trail quarters average earning beat be past month share orthofix have outperformed industry belong stock have gain compare industry rise conformis inc cfms free report be currently used ifit image implant technology printing platform manufacture ijig furthermore conformis be plan use same make certain component customize knee replacement implant notably company receive fda approval use ifit printing technology manufacture metal femoral implant component itotal cr used direct metal laser sintering zack rank company have long term earning growth rate growth score current year estimate revision trend stock have be encourage estimate move upward compare downward movement past month company have deliver positive earning surprise trail quarters average earning beat be past month share conformis have outperformed industry belong stock have gain compare industry rise go article stratasys medtronic plc mdt free report adopt printing technology concept testing technological development rapid prototyp anatomical modele development test fixture application end technology have result lower project cost faster process time zack rank company have long term earning growth rate company have deliver positive earning surprise trail quarters average earning beat be past month share medtronic have outperformed market stock have gain compare decline conclusiona say strike iron be hot be opportune time cash rapidly rise printing trend investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
70,ZBH,zimmer biomet holding inc zbh free report be set report fourth quarter result jan market open last quarter company post negative earning surprise however zimmer biomet have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement key prior quarter company be expect gain strength surgical sport medicine foot ankle extremity trauma arm last report quarter revenue be drive surgical business sport medicine offering such gel quattro link moreover solid uptake plate system foot ankle portfolio boost segment performance company witness strength intellicart system fluid waste management historically strong performance key brand acquisition increase focus sale force specialization have be partially offset adverse impact supply issue continue pricing pressure segment zack consensus estimate revenue reflect increase year quarter report number zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote be also upbeat spine thoracic spine cmf segment be expect deliver quarter promising performance spine category zimmer biomet continue gain strong uptake mobi cervical disc also be look forward top line contribution company launch product avenue tlif cage vitality vital spinal fixation system unite state october moreover ldr holding acquisition have insignificant contribution top line basis point third quarter initial phase integration be expect contribute basis point full year revenue cer also management be hopeful gain significant cross selling opportunity acquisition provide back strong spine sale force unite state continue uptake trauma plate system sternalock blu sternalock primary closure system well ribfix blu thoracic fixation system thoracic arm buoy optimism zack consensus estimate spine revenue indicate rise year quarter overall fourth quarter revenue be project prior year quarter here be other factor influence zimmer biomet fourth quarter result look focuse execution zimmer biomet sale team expect global adoption rate flagship personalize knee system persona be impressive be also upbeat launch persona partial knee system last september knee system marked latest addition company portfolio personalize anatomically design knee implant system also zimmer biomet release ray base patient specific instrument psi knee system first half buoy optimism be world first ce marked surgical plan system allow patient specific implant position solely utilize ray technology development be expect boost fourth quarter revenue zack consensus estimate knee revenue indicate uptick year quarter emerge market have always be significant revenue generate source zimmer biomet recent economic downturn latin america company manage drive growth operation other emerge market especially asia pacific emea europe middle east africa zack consensus estimate third quarter revenue emea indicate improvement year quarter moreover zack consensus estimate third quarter revenue apac indicate rise year quarter meanwhile macroeconomic uncertainty unfavorable currency fluctuation have be dent sale company past few quarters company have also be deal pricing pressure regard zimmer biomet face negative pricing pressure approximately last report quarter absence favorable change line headwind reflect company fourth quarter result second half management continue expect impact reduce sale expectation continue spending critical program rise manufacturing cost warsaw north campus facility earning whisper proven model do not conclusively show earning beat zimmer biomet quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp zimmer biomet have earning esp be most accurate estimate be peg zack consensus estimate stand zack rank zimmer biomet carry zack rank sell please note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision momentum zack consensus estimate fourth quarter adjust earning reflect decline year quarter stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
71,ZBH,zimmer biomet holding inc zbh free report reach new milestone field total shoulder arthroplasty recent food drug administration fda approval sidusstem free shoulder system unite state follow approval sidus system be available country first quarter total shoulder arthroplasty solution claim benefit patient good bone stock also same time complain osteoarthritis post traumatic arthrosis focal avascular necrosis humeral head have undergo previous surgery shoulder do not compromise fixation zimmer biomet system be design restore patient anatomy preserve bone stock offer improve pre post operative patient outcome be encourage note sidus stem free shoulder system offer minimal bone resection total shoulder arthroplasty zimmer biomet claim advanced approach reduce pain restore range motion sidus system be first introduce europe company initiate clinical study unite state go strong clinical performance sidus stem free shoulder system have demonstrated time zimmer biomet seem highly optimistic show impression customer adoption article publish orthospinenews global shoulder arthroplasty market be value same be expect scale register cagr forecast period promising datum indicate timely strategic role latest fda approval be go play favor zimmer biomet solid stock performance last day zimmer biomet have be trading broader industry company have gain versus broader industry rise also company have outperformed gain same time frame zack rank key pickszimmer biomet carry zack rank sell better rank stock broader medical space be abiom inc abmd free report tactile system technology tcmd free report intuitive surgical inc isrg free report carry zack rank buy see complete list today zack strong buy rank stock here abiom have long term expect earning growth rate stock have rally last year tactile system have long term expect growth rate stock have soar last year intuitive surgical have long term expect growth rate last month stock have rally medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
72,ZBH,here be stock add zack rank strong sell list today netease inc nte free report be operator interactive online community zack consensus estimate current year earning have be revise downward last day zimmer biomet holding inc zbh free report be designer musculoskeletal healthcare product solution zack consensus estimate current year earning have be revise downward last day post holding inc post free report be consumer package good hold company zack consensus estimate current year earning have be revise downward last day qorvo inc qrvo free report be provider radio frequency rf solution technology zack consensus estimate current year earning have be revise downward last day axis capital holding limit axs free report be provider various specialty insurance reinsurance product zack consensus estimate current year earning have be revise downward last day view entire zack rank list
73,ZBH,zimmer biomet holding inc zbh free report recently announce positive result progress ii treatment knee osteoarthritis oa datum study base patient symptomatic knee oa pain trial site europe demonstrated safety efficacy nstride autologous protein solution aps kit therapy company investigator prepared aps used zimmer biomet nstride aps kit concentrate inflammatory cytokine growth factor sample enrolled patient blood delivery single intra articular injection knee joint outcome show significant improvement percentage change baseline pain score comparable safety saline notably nstride aps kit be market europe japan asia pacific well however kit be commercially unavailable unite state be clinical evaluation country furthermore positive finding confirm basis more trial namely progress iv progress development knee businesslast quarter revenue derive knee be year year however company be putt consistent effort improve knee business regard note zimmer biomet announce global launch persona partial knee system aug advanced addition company portfolio personalize anatomically design knee implant system major development zimmer biomet knee business be unveil ray base patient specific instrument know psi knee system june be world first ce marked surgical plan system enable patient specific implant position sole use ray technology market prospectsper report globaldata oa market be expect reach value major market cagr unite state continue dominate oa market even end target year total sale be accredit country account take grow oa market consideration believe latest development boost company sale segment solid stock performance last day zimmer biomet have be trading broader industry company have gain versus broader industry decline also company have outperformed gain same time frame zack rank key pickszimmer biomet carry zack rank sell few better rank medical stock be bruker corporation brkr free report align technology inc algn free report cheme corporation che free report notably bruker align technology sport zack rank strong buy cheme carry zack rank buy see complete list today zack rank stock here bruker have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have sky-rocket year cheme have long term expect earning growth rate stock have soar year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
74,ZBH,zimmer biomet holding inc zbh free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame upside be drive passage tax reform bill propose lower maximum corporate tax company have see negative estimate revision past month zack consensus estimate have remain unchanged suggest be trouble road so make sure keep eye stock go forward see recent move higher last zimmer biomet currently have zack rank sell earning esp be positive zimmer biomet holding inc price zimmer biomet holding inc price zimmer biomet holding inc quotea better rank stock medical product industry be bio rad laboratory inc bio free report currently sport zack rank strong buy see complete list today zack rank stock here be zbh go predict see other think medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
75,ZBH,here be stock add zack rank strong sell list today netease inc nte free report be operator interactive online community zack consensus estimate current year earning have be revise downward last day zimmer biomet holding inc zbh free report be designer musculoskeletal healthcare product zack consensus estimate current year earning have be revise downward last day maximus inc mms free report be business process service provider zack consensus estimate current year earning have be revise downward last day dineequity inc din free report be owner franchisor operator full service restaurant zack consensus estimate current year earning have be revise downward last day public joint stock company mobile telesystem mbt free report be telecom company zack consensus estimate current year earning have be revise downward last day view entire zack rank list
76,ZBH,zimmer biomet holding inc zbh free report report third quarter adjust earning share ep year year adjust earning also miss zack consensus estimate cent reportedly net earning come cent share mark slash year figure revenue detailszimmer biomet third quarter net revenue come mark drop constant exchange rate cer year year recently include ldr hold contribute basis point bps top line exclude contribution ldr hold quarter revenue decline cer year year revenue however remain line zack consensus estimate zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc quote revenue generate americas quarter be year year cer same emea europe middle east africa gross asia pacific however register growth cer reach segmentsrevenue derive knee be year year cer hip too record decline cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record marginal improvement cer dental be quarter other revenue drop marginsa dismal topline performance rise cost product sell result gross margin contraction third quarter zimmer biomet gross margin deteriorate bps quarter selling general administrative expense be research development expense also decline accordingly adjust operate margin expand bps quarter cash positionzimmer biomet exit third quarter cash cash equivalent compare second quarter end total long term debt be compare end second quarter year date operate cash flow be compare year period company also paid dividend third quarter outlook base dull topline show zimmer biomet have lower full year guidance company currently expect register revenue range represent growth cer range earlier prediction be growth include contribution approximately bps ldr transaction current zack consensus estimate revenue be peg guide range adjust ep expectation have be forecast range lower earlier range year current zack consensus estimate ep be peg much ahead current guidance fourth quarter company expect revenue range represent growth negative positive year year cer additionally adjust ep fourth quarter be expect be range takezimmer biomet end quarter dismal note earning remain zack consensus estimate revenue be marginally line same be disappoint company decline sale performance most core segment accord company challenge top line result be due pace supply recovery certain key brand softened domestic market condition slower anticipate sale recapture particularly unite state lower guidance also add concern indicate little chance recovery ahead however look forward ongoing synergy ldr hold acquisition broaden complement company musculoskeletal offer be also impressed strong strategic financial goal combine entity expect reach zack rank key pickszimmer biomet have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
77,ZBH,jun issue update research report nuvasive inc nuva free report be upbeat company flourishing international business hold immense opportunity however highly competitive landscape be concern zack rank hold company lead global medical device company global spine market focuse develop minimally disruptive surgical product procedurally integrate solution spine have be outperform industry past month stock have gain compare industry rise be upbeat nuvasive international business record growth sixth consecutive quarter first quarter company see strong sale growth geography emerge market also perform well strong growth south africa saudi arabia asia pacific grow double digit strong result japan reintroduction xlif further nuvasive healthy cash balance support plan pursue acquisition develop product meanwhile presence large number player have make medical device market intensely competitive orthopedic industry particular be extremely competitive presence bellwether zimmer biomet holding zbh free report stryker corporation syk free report other also margin drag pricing pressure reimbursement issue continue be other major headwind key picka better rank stock broader medical sector be intuitive surgical isrg free report sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
78,ZBH,have be month last earning report zimmer biomet holding inc zbh free report share have lose time frame recent negative trend continue lead next earning release be zbh due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningszimmer biomet report first quarter adjust earning share year year ahead zack consensus estimate reportedly net earning come cent share compare year quarter revenue detailsfirst quarter net sale come mark increase constant exchange rate cer year year net sale also surpass zack consensus estimate quarter review sale generate americas totale year year cer same emea europe middle east africa gross asia pacific however register growth cer segmentssale knee be year year cer hip record drop cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf be cer dental decline other revenue fall marginsgross margin come reflect contraction bps first quarter selling general administrative expense be further research development expense rise adjust operate margin decline bps quarter cash positionzimmer biomet exit first quarter cash cash equivalent compare end total long term debt be compare end first quarter operate cash flow be compare year quarter company also paid dividend quarter company have issue full year guidance sale be project grow range management project sale growth figure include basis point impact favorable currency movement zack consensus estimate revenue be peg current year adjust ep be expect be band zack consensus estimate coincide high end guide range have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower zimmer biomet holding inc price consensus zimmer biomet holding inc price consensus zimmer biomet holding inc quotevgm scoresat time zbh have average growth score grade same score momentum front charting somewhat similar path stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable value investor look growth momentum outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift interestingly zbh have zack rank hold expect line return stock next few month
79,ZBH,zimmer biomet holding inc zbh free report recently announce receipt clearance fda zyston strut open titanium interbody spacer system be expect revitalize spine division notably product be company first titanium spinal implant be build used printing technology zyston strut open titanium system zyston strut open titanium system be family lumbar cage be available various size meet patient requirement further system have be develop increase strength capacity graft visualization interbody spacer spinal fusion case also encompass surgical instrument enable insertion manipulation elimination implant be printing technology also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub further printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr zimmer biomet latest offer zyston strut open titanium system be build used printing process allow physician develop unique cage architecture maximize graft volume implantation zimmer biomet have announce receipt clearance unite bridge fixation system foot ankle business notably innovative product be result combination company osseoti porous metal technology printing process glimpse spine divisionzimmer biomet spine thoracic spine cmf segment revenue be cer first quarter company have be face revenue dissynergy related spine sale force integration meanwhile be upbeat recent fda nod be expect expand company lumbar spacer portfolio include peek optima trabecular metal technology allograft note zimmer biomet have be gain strong uptake mobi cervical disc also company recently launch product avenue tlif cage well vitality vital spinal fixation system unite state market potentialper report market research future safely conclude latest development help zimmer biomet cash opportunity spinal implant market accord report global spinal implant market be expect see cagr roughly price performanceover past month zimmer biomet have be observed underperform industry stock have decline compare rise industry believe latest fda approval boost investor faith stock zack rank stock considerzimmer biomet currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
80,ZBH,sunday china put trade tension aside hope reach stable broad trade agreement previously risk stock begin rise seem be room profit formerly questionable market read stock investor reconsider trade war be put hold stock buynorbord osb free report manufacturer wood base panel be first company investor keep radar earlier year have enact tariff import steel tariff import aluminum president trump announcement enactment tariff late february mid march many construction company reliant steel everyday process be thought fail other construction company such norbord canadian company have be catch crossfire tariff other import good be impose be thought be hardest hit reflective company zack rank sell time still norbord continue thrive share increase march date recently thing have become even more bullish osb current quarter next quarter ep estimate revision have see agreement upside push company zack rank strong buy top osb consider great value stock company currently sport ratio cash flow share compare favorably industry average share boee ba free report be company thought struggle face trade tension late february late march share price drop largely due chinese government announcement order plane boee largest international competitor airbus boee be also consider be crosshair chinese retaliation new tariff point late march share have rebound date company be currently zack rank buy strong growth stock proven historical cash flow growth current cash flow growth astonishing company deserve grade growth category style score system boee also sport net margin more double industry average stock reconsiderwhile investor consider buy stock option such zimmer biomet holding zbh free report have potential be not clear cut medical company see massive drop march due chinese venture risk retribution tariff time period zimmer be zack rank strong sell point company have rise zack rank hold zimmer share price have steadily be decrease loom trade war be present ultimately be aggravate threat chinese relation early april stock have fought back slightly increase company grade value style score come drop share price relative lower guidance release earning report zimmer cf ratio be now trading massive discount industry average so drop have bring stock interesting value territory consider trade war stall be stock bounce back continue see improvement share price investor be worry continue tension action most likely result fresh volatility hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
81,ZBH,ever undergo reconstructive orthopedic surgery yes then have be implanted personalize joint replacement technology indiana base lead orthopedic medical device manufacturer zimmer biomet holding inc zbh free report formerly know zimmer holding june legacy zimmer complete acquisition biomet operation more country company market orthopedic reconstructive spinal trauma device biologic dental implant related surgical product more country currently zimmer biomet have zack rank sell change follow first quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zimmer biomet report first quarter adjust earning share beating zack consensus estimate revenue zimmer biomet post revenue have surpass zack consensus estimate revenue key stat first quarter revenue derive zimmer biomet knee segment be increase year year hip record sale compare prior year quarter revenue surgical sport medicine foot ankle extremity trauma improve year year zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quotemajor factor year year revenue growth knee hip segment buoy optimism company witness strong performance asia pacific emea region constant exchange rate zimmer biomet also issue full year sale earning guidance stock price follow earning release share price do not show movement pre market trading session check back later full zimmer biomet earning report later more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
82,ZBH,trade war cacophony have spread far wide not spare investment world conflict world biggest economy have lead dow fall more point just day last week be gradually recover market be still fraught possibility other outbreak sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector face brunt trade dispute current most economist have initially expect china be fast adopt stance square america advantage point import tariff game response trump propose imposition annual tariff chinese product beij have announce initial reciprocal tariff roughly import unite state be supposedly prepare bolder counter attack wake tariff threat nobel prize winning economist robert shiller have warn impending economic crisis meanwhile bloomberg report state unite state maintain lead trade conflict china be unite state extent be monopsony market large number buyer thus nation stop purchasing chinese product china not be able channelize surplus canada indonesia same price however china not be able adopt tit tat strategy do not import same scale unite state accordingly follow last week crash market be slowly look news nation be likely resolve issue mutually be fuel recovery however talk extinguish possibility trade war completely be yet be see meanwhile investor be catch america first make china web be medical device catch storm state earlier trade representative robert lighthizer have identify healthcare sector be subject tariff more specifically trump have consider biomedicine high performance medical device include china advanced chemical medical equipment respectively needless say have trigger decline sector follow news chance china retaliation loss be widespread medical device sector bigwig take severe blow note sector have gain significantly profit earn number medical device company bric nation go market realist report company medtronic plc mdt free report becton dickinson company bdx free report abbott other see considerable weakness mar talk china trade war start do round stock be gradually revive rise chance nation negotiating certain term investor consider still extremely vulnerable widely expose trade conflict give huge business network mainland china have shortlist stock be face brunt tumultuous market condition zimmer biomet holding inc zbh free report zack rank strong sell lose mar note company have be investing heavily cash chinese reconstructive trauma market strategic investment region past several quarters improve operational sale performance be yielding result fourth quarter company witness improvement asia pacific business solid distributor order china particularly demonstrated strong growth thus form retaliation china impact company zimmer biomet holding inc price zimmer biomet holding inc price zimmer biomet holding inc quotemedtronic last report quarter medtronic business china show strength grow double digit accord company next decade china be expect be biggest health care market needless say zack rank hold company be expending large amount cash strengthen business market company be focuse develop public private partnership well execute channel optimization strategy see complete list today zack rank strong buy stock here medtronic plc price medtronic plc price medtronic plc quoteover last few year abbott free report have be lead emerge market investment trend total sale come region zack rank stock core establish pharmaceutical division epd business operate solely emerge geography lead position chinese pharmaceutical market brand generic last report quarter well china demonstrated double digit growth epd trade war not stock be extremely vulnerable position broad network diversify business base china abbott laboratory price abbott laboratory price abbott laboratory quotebreaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
83,ZBH,here be stock add zack rank strong sell list today zimmer biomet holding inc zbh free report be designer manufacturer musculoskeletal healthcare product solution zack consensus estimate current year earning have be revise downward last day simpson manufacturing co inc ssd free report be designer manufacturer build construction product zack consensus estimate current year earning have be revise downward last day pier import inc pir free report be retailer decorative accessory such furniture candle zack consensus estimate current year earning have be revise downward last day newell brand inc nwl free report be designer distributor consumer commercial product zack consensus estimate current year earning have be revise downward last day imax corporation imax free report be owner operator entertainment technology company zack consensus estimate current year earning have be revise downward last day view entire zack rank list
84,ZBH,zimmer biomet holding inc zbh free report report fourth quarter adjust earning share year year line zack consensus estimate reportedly net earning come compare year quarter cent notably report net earning include time tax benefit approximately recently enact tax reform legislation full year adjust earning share come line zack consensus estimate however figure beat year number revenue detailsfourth quarter net sale come mark increase constant exchange rate cer year year net sale also surpass zack consensus estimate net sale totale surpass zack consensus estimate figure also beat year number full year sale increase prior year cer exclude approximately basis point contribution ldr hold corporation acquisition quarter sale generate americas be year year cer same emea europe middle east africa gross asia pacific however register growth cer segmentssale knee be year year cer hip record increase cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record marginal improvement cer dental be quarter other revenue increase marginsgross margin come reflect expansion bps fourth quarter selling general administrative expense be however research development expense decline adjust operate margin expand bps quarter cash positionzimmer biomet exit year cash cash equivalent compare end third quarter total long term debt be compare end precede quarter full year operate cash flow be compare year period company also paid dividend fourth quarter company have issue first quarter guidance sale be project range represent change negative positive negative negative constant currency basis compare prior year quarter be inclusive negative impact related approximately less bill day compare year earlier quarter current zack consensus estimate lie guide range adjust ep quarter be expect remain band zack consensus estimate remain guide range takezimmer biomet end quarter positive note be also encourage company consistent effort product renovation research development be optimistic synergy ldr hold acquisition broaden complement company musculoskeletal range be also impressed strong strategic financial goal combine entity expect reach however be disappoint company decline sale knee segment cer zack rank key pickszimmer biomet have zack rank sell few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately surpass year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter increase year year don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now be reissue article correct mistake original version publish earliertoday longerbe rely
85,ZBH,zimmer biomet holding inc zbh free report report first quarter adjust earning share year year ahead zack consensus estimate reportedly net earning come cent share compare year quarter revenue detailsfirst quarter net sale come mark increase constant exchange rate cer year year net sale also surpass zack consensus estimate quarter review sale generate americas totale year year cer same emea europe middle east africa gross asia pacific however register growth cer segmentssale knee be year year cer hip record drop cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf be cer dental decline other revenue fall zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc margin come reflect contraction bps first quarter selling general administrative expense be further research development expense rise adjust operate margin decline bps quarter cash positionzimmer biomet exit first quarter cash cash equivalent compare end total long term debt be compare end first quarter operate cash flow be compare year quarter company also paid dividend quarter company have issue full year guidance sale be project grow range management project sale growth figure include basis point impact favorable currency movement zack consensus estimate revenue be peg current year adjust ep be expect be band zack consensus estimate coincide high end guide range takezimmer biomet end quarter positive note be also encourage company consistent effort product renovation research development be optimistic synergy ldr hold acquisition broaden complement company musculoskeletal range be also impressed strong strategic financial goal combine entity expect reach however company decline sale knee hip other segment cer disappoint moreover supply headwind related major brand company knee hip segment affected first quarter performance extent zack rank key pickszimmer biomet have zack rank sell few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter adjust earning share beating zack consensus estimate revenue come exceed consensus estimate cheme post first quarter adjust earning share beating zack consensus estimate revenue come steering past zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
86,ZBH,ever undergo reconstructive orthopedic surgery yes then have be implanted personalize joint replacement technology indiana base lead orthopedic medical device manufacturer zimmer biomet holding inc zbh free report formerly know zimmer holding june legacy zimmer complete acquisition biomet operation more country company market orthopedic reconstructive spinal trauma device biologic dental implant related surgical product more country currently zimmer biomet have zack rank sell change follow fourth quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate stand share last day zimmer biomet adjust earning share line zack consensus estimate zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote revenue zimmer biomet post revenue have surpass zack consensus estimate revenue key stat fourth quarter revenue derive zimmer knee segment be increase year year hip record sale compare prior year quarter revenue surgical sport medicine foot ankle extremity trauma improve year year major factor year year revenue growth business segment buoy optimism company witness strong asia pacific performance constant exchange rate company also issue first quarter sale earning guidance stock price follow earning release share price do not show movement pre market trading session check back later full zimmer biomet earning report later don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
87,ZBH,fourth quarter earning season have commence positive note most sector decent picture participant have report jan total earning company be year year higher revenue beating earning estimate surpass top line expectation notably company be report earning week latest earning preview overall earning fourth quarter be expect increase growth revenue indicate improve growth projection previous quarter drive corporate tax overhaul relatively healthy job datum factor have boost corporate earning stoke investment base pattern fourth quarter be expect register modest double digit percentage earning growth year year basis medtech earning so farmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be evident result medtech heavyweight abbott free report intuitive surgical isrg free report company exit fourth quarter solid note beating zack consensus estimate count upbeat fy guidance also instill confidence fourth quarter earning growth rate medical sector be peg revenue growth upcoming releaseslet take look major other medtech stock slate release quarterly report jan stryker corporation syk free report result be schedule release market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be year year basis stryker recently announce better expect preliminary net sale result fourth quarter full year net sale be estimate year quarter constant currency basis figure beat zack consensus estimate buoy prospect quantitative model indicate earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate stryker earning esp be uncover best stock buy sell re report earning esp filter stryker carry zack rank read more core segmental growth aid stryker earning stryker corporation price consensus stryker corporation price consensus stryker corporation quotezimmer biomet holding inc zbh free report be set report result market open notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be project year year basis solid prospect company surgical sport medicine foot ankle extremity trauma arm macroeconomic uncertainty unfavorable currency fluctuation have be dent sale past few quarters company have be deal pricing pressure regard zimmer biomet witness negative pricing pressure approximately last quarter absence favorable change line headwind reflect company fourth quarter result read more arm drive zimmer biomet earning result proven model do not conclusively show earning beat zimmer biomet quarter zimmer biomet have earning esp stock carry zack rank sell see complete list today zack rank strong buy stock here zimmer biomet holding inc price consensus zimmer biomet holding inc price consensus zimmer biomet holding inc quotealign technology inc algn free report be set report result market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be cent year year basis align technology achieve milestone patient undergo treatment flagship clear aligner system invisalign november company have be adopt several strategy drive adoption core invisalign product line company receive patent align technology smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align technology collaborate digital design recent past read more invisalign drive align technology earning positive development proven model do not conclusively show align technology be likely beat earning quarter align technology have earning esp stock carry zack rank align technology inc price consensus align technology inc price consensus align technology inc quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
88,ZBH,point person life need assist medical device age have hip replacement knee replacement pacemaker current context nothing appear be more apt remark make aimee mullin american athlete consider grow prominence orthopedic industry seem prosthetic generation be indeed new market intelligence report bis research publish cision global orthopedic device market be worth be estimate be worth end cagr joint reconstruction replacement device segment be highest revenue generator north america have highest share orthopedic device market be expect lead same encouragingly asia pacific be also estimate catch cagr niche space grand view research report publish becker healthcare thus investor be keen place bet healthcare space long term gain orthopedic market undoubtedly hold immense potential here take look major factor have be drive global orthopedic industry last couple year major market moversagee populaceone major factor drive orthopedic market be age population report publish global market insight population be expect be globally poor life stylepoor eating habit smoking drink lack physical activity also drive demand orthopedic market rise healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand report center medicare medicaid service publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue rise incidence diabetesdiabete obesity also fuel growth market globally diabetes market be expect touch cagr transparency market research report positive tiding regulatory orthopedic market be ride high recent fda nod product launch zimmer biomet holding inc zbh free report reach new milestone field total shoulder arthroplasty recent fda approval sidusstem free shoulder system furthermore company launch vitality vital spinal fixation system unite state global launch persona partial knee system nuvasive inc nuva free report announce receipt fda clearance company precice system nuvasive specialize orthopedic nso further nephew snn free report announce full commercial release cruciate retain journey ii xr total knee arthroplasty tka unite state japan recently robotic surgery boost technology company be try expand robot rather complex surgery report technavio global orthopedic surgical robot market be estimate witness cagr view abovemention factor number bigwig be spending lump sum continuously innovate develop device improve efficacy side effect regard most noteworthy be stryker corporation syk free report mako be stryker robotic arm assist surgery platform recently stryker launch robotic arm assist total knee arthroplasty application use mako system medical device major johnson johnson jnj free report recently announce acquisition orthotaxy be privately hold developer software enabled surgery technology include differentiate robotic assist surgery solution printing technology orthopedic device company be try leverage be printing report future market insight publish cision orthopedic implant application category global print medical device market be expect be worth time frame cagr regard stryker tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation device recently win fda nod stock focuswe have select company believe be well poise give encourage prospect orthopedic market stryker corporation company have long term earning growth rate current quarter estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly zack consensus estimate increase share company year historical growth rate be also favorable compare industry stryker share price movement past year have be favorable company yielded return almost better industry orthofix international ofix free report company have long term earning growth rate company year earning growth rate also compare favorably past month share orthofix have outperformed industry belong stock have gain compare industry rise company recently announce fda approval limit market launch forza xp expandable spacer system johnson johnson company have long term earning growth rate estimate revision current year have be solid estimate move upward compare movement opposite direction past month resultantly consensus estimate increase share company year historical growth rate also compare favorably industry share have increase past month compare favorably increase witness industry more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
89,ZBH,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put zimmer biomet holding inc zbh free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front zimmer biomet have trail month pe ratio see chart level actually compare pretty favorably market large pe compare focus stock long term pe trend current level put zimmer biomet current pe ratio slightly midpoint be past year further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point zimmer biomet have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead zimmer biomet stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now zimmer biomet have ratio be marginally lower average come right now also see chart be somewhat high stock particular past few year anything suggest level undervalue trading least compare historical norm broad value outlookin aggregate zimmer biomet currently have value style score putt top stock cover look make zbh solid choice value investor other key metric make pretty clear too example peg ratio zimmer biomet be just level be noticeably lower industry average peg ratio be modify pe ratio take account stock earning growth rate additionally cf ratio great indicator value come be considerably better industry average clearly zbh be solid choice value front multiple angle stock overall zimmer biomet be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give zbh vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be disappointing current quarter have see estimate go lower past day compare none higher full year estimate have see downward upward revision same time period have have noticeable impact consensus estimate current quarter consensus estimate have fall past month full year estimate have dip see consensus estimate trend recent price action stock chart zimmer biomet holding inc price consensus zimmer biomet holding inc price consensus zimmer biomet holding inc somewhat bearish trend be stock have just zack rank hold be look line performance company term bottom linezimmer biomet be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year sector have clearly underperform broader market see so value investor want estimate analyst sentiment broader factor turn favorable name first once happen stock be compelling pick make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
90,ZBH,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report recently announce have initiate treatment recently introduce halcyon system treatment be provide penn medicine patient suffering head neck cancer notably treatment used halcyon platform be cost effective be short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon unit glancevarian medical have be take initiative gain customer broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna third quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide halcyon receive clearance ce mark european directive allow varian medical start selling system unite state management regulatory clearance china japan follow next year quarter varian medical book several order country australia belgium india morocco romania russia turkey market prospectsstrong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian medical datum market market reveal global radiotherapy market be project reach worth cagr meanwhile other important stock broader medical sector be zimmer biomet holding zbh free report abiom inc abmd free report intuitive surgical isrg free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
91,ZBH,mazor robotic ltd mzor free report recently receive ce mark approval mazor surgical assurance platform approval allow mazor robotic partner medtronic mdt free report commercialize co promote market mazor platform country recognize ce mark mazor robotic medtronic have sign deal distribute mazor mazor robotic spine surgery system medtronic have make third tranche investment mazor robotic recently regard note mazor robotic recently report second quarter revenue approximately compare year quarter revenue upside be drive strong mazor system sale increase procedure volume last report second quarter mazor robotic receive purchase order mazor system unite state expect ce mark drive order system accord report mordor intelligence global market spinal surgery device have be estimate reach worth cagr period consider opportunity niche see company latest development strategic however company be face tough competition industry well establish player likestryker corporation syk free report zimmer biomet holding inc zbh free report estimate revision trend estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have narrow loss cent share loss cent stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
92,ZBH,zimmer biomet holding inc zbh free report announce global launch persona partial knee system aug be advanced addition company portfolio personalize anatomically design knee implant system acquisition biomet persona partial knee system be first develop product consolidated company persona partial knee system provide surgeon comprehensive system implant instrument offer excellent fit accuracy operate room zimmer biomet fix bearing system complement mobile bearing oxford partial knee company follow launch first surgery persona partial knee system be success last report second quarter revenue knee segment be year year cer company have be observed put consistent effort boost business take consideration grow global knee implant market believe latest development boost company sale niche regard note accord bcc research report global market joint reconstruction replacement be expect increase nearly cagr market be expect reach worth cagr european japanese market be estimate reach worth respective cagr major development zimmer biomet knee business be thelaunch ray base patient specific instrument psi knee system be world first ce marked surgical plan system enable patient specific implant position solely used ray technology past month zimmer biomet have be trading broader industry company have gain compare gain broader industry zack rank key pickszimmer biomet carry zack rank sell few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
93,ZBH,bid expand advanced material science range nuvasive inc nuva free report recently announce vertera spine buyout however term acquisition agreement have be keep wrapped nuvasive pioneer apply procedurally integrate solution minimally disruptive spine surgery aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state deal also lend company dimensional porous interbody technology peek titanium material notably company have introduce few new feature modulus xlif build fully porous titanium implant create dimensional manufacturing process design match porosity stiffness bone encouragingly note company spinal hardware business comprise implant fixation product magec eos spinal brace lengthen system precice limb lengthen system register growth last report quarter nuvasive be leave stone unturned gain traction fast grow spine market regard company have be steadily focuse product development moreover company claim have active corporate development pipeline include number strategic investment acquisition partnership opportunity notably first quarter company launch first interbody device mlx tlx used lumbar fusion procedure report becker spine review global minimally invasive spine surgery market be expect witness cagr also report technavio global spinal implant market be expect witness cagr roughly period thus give current market potential believe company be right track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio moreover zimmer biomet range thoracolumbar product form comprehensive portfolio minimally invasive spine surgery past month nuvasive have underperform broader industry period company have lose compare gain broader industry expect company make comeback latest development zack rank key picknuvasive carry zack rank hold better rank medical stock be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
94,ZBH,here be stock add zack rank strong sell list today zimmer biomet holding inc zbh free report be manufacturer marketer musculoskeletal healthcare product solution zack consensus estimate current year earning have be revise downward last day food hold corp usfd free report be marketer distributor fresh frozen dry food food product zack consensus estimate current year earning have be revise downward last day leju holding limit leju free report be online offline real estate service provider zack consensus estimate current year earning have be revise downward last day flower food inc flo free report be producer marketer bakery product zack consensus estimate current year earning have be revise downward last day columbia property trust inc cxp free report be equity real estate investment trust zack consensus estimate current year earning have be revise downward last day view entire zack rank list
95,ZBH,dec issue update research report warsaw base zimmer biomet holding inc zbh free report company carry zack rank sell last month lead musculoskeletal healthcare company have be trading broader industry macroeconomic uncertainty pricing pressure unfavorable currency fluctuation stock have lose value versus broader industry gain management zimmer biomet be grapple headwind such supply delay certain product cause inability back lose customer unite state tap new one softened domestic market condition impact consecutive hurricane significant price reduction indian knee market trim guidance issue last quarter result announcement add concern indicate little chance recovery ahead estimate revision trend also remain unfavorable estimate have moved south none opposite direction past couple month stock have see zack consensus estimate current year earning be revise cent downward period share positive note look forward synergy expect be draw recently complete ldr hold acquisition broaden complement company musculoskeletal offer be line strategy grow inorganic mean focuse mega buyout also pin high hope strong tactical financial goal combine entity aim reach now deal have be seal zimmer biomet have be late work fortify foothold emerge market potential provide long term opportunity good news be company plan investment region several quarters view enhance operational sale performance be also yielding result key picksa few better rank medical stock be bio rad laboratory bio free report baxter international inc bax free report icu medical inc icui free report notably bio rad laboratory sport zack rank baxter international inc icu medical inc sport zack rank buy see complete list zack rank stock here bio radha long term growth estimate next quarter stock have rally roughly year baxter international have growth estimate next quarter stock have rally roughly year icu medical have long term growth estimate next year stock have rally roughly year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
96,ZBH,nov issue update research report warsaw base zimmer biomet holding inc zbh free report company carry zack rank sell last month lead musculoskeletal healthcare company be trading broader industry macroeconomic uncertainty pricing pressure unfavorable currency fluctuation stock have gain versus broader industry gain company third quarter result fall short zack consensus estimate own expectation management zimmer biomet be grapple headwind such supply delay certain product lead inability regain lose customer unite state tap new one softened domestic market condition impact consecutive hurricane significant price reduction indian knee market trim guidance add concern indicate little chance recovery ahead estimate revision trend also remain unfavorable estimate move south none opposite direction past month stock have see zack consensus estimate be revise cent downward period share positive note look forward expect synergy be draw recently complete ldr hold acquisition broaden complement company musculoskeletal offer be line strategy grow inorganic mean focuse mega buyout be also impressed strong strategic financial goal combine entity anticipate reach now deal have be close zimmer biomet have be late work strengthen foothold emerge market provide long term opportunity company strategic investment region several quarters view enhance operational sale performance be yielding result key picksa few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report sporting zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technologyha long term expect earning growth rate stock have gain year myriad geneticsha long term expect earning growth rate stock have surge year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
97,ZBH,ever undergo reconstructive orthopedic surgery yes then have be implanted personalize joint replacement technology indiana base lead orthopedic medical device manufacturer zimmer biomet holding inc zbh free report formerly know zimmer holding june legacy zimmer complete acquisition biomet operation more country company market orthopedic reconstructive spinal trauma device biologic dental implant related surgical product more country currently zimmer biomet have zack rank hold change follow third quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate stand share last day zimmer biomet adjust earning share have miss estimate cent zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quoterevenue zimmer biomet post revenue be line zack consensus estimate revenue key stat third quarter revenue derive zimmer knee segment be year year hip record sale compare prior year quarter revenue surgical sport medicine foot ankle extremity trauma improve year year major factor management revenue growth do not meet company expectation due production delay certain key brand slower expect sale recapture previously affected customer unite state company also update sale earning guidance stock price follow earning release share price do not show movement pre market trading session check back later full zimmer biomet earning report later more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
98,ZBH,be big week earning company expect report include most watch name street tracey go chart so don have find best bunch be report early week company have excellent earning track record beating nearly quarter year not easy beat quarter year be only couple dozen company be able beat quarter consistently course earning beat doesn necessarily mean stock rise other factor also play stock performance include guidance investor sentiment company be just favor industry be name be watch lead week earning star start week mastercard free report have miss just once year chart look lot competitor visa share new high visa beat mastercard do same electronic art ea free report have miss only time come just quarters last quarter turn massive beat share bust new high again week allergan agn free report have only miss twice last year biopharmas be really favor so stock be multus year lows be buy opportunity zimmer biomet zbh free report be come rare miss last quarter share have be choppy investor haven completely throw towel share yet groupon grpn free report hasn miss share have be relegate club several year last quarter be solid good quarter put even more fire share want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
99,ZBH,zimmer biomet holding inc zbh free report be expect beat earning report third quarter result nov open bell last quarter company earning miss zack consensus estimate however report average beat trail quarters let see thing be shape prior announcement key prior quarter company be expect gain strength surgical sport medicine foot ankle extremity trauma arm revenue be drive surgical business sport medicine offering such gel quattro link last report quarter moreover solid uptake plate system foot ankle portfolio boost segment performance zack consensus estimate revenue reflect increase year quarter zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote be also upbeat spine thoracic spine cmf segment be expect deliver quarter promising performance spine category zimmer biomet continue gain strong uptake mobi cervical disc moreover initial phase integration ldr holding acquisition be expect contribute approximately basis point company top line be report quarter also management be hopeful gain significant cross selling opportunity ldr acquisition provide back integrate spine sale force unite state also continue solid uptake sternalock blu sternalock primary closure system well ribfix blu thoracic fixation system thoracic arm buoy optimism zack consensus estimate spine cmf revenue indicate rise year quarter here be other factor influence zimmer biomet third quarter result look focuse execution zimmer biomet sale team expect global adoption rate company flagship personalize knee system persona be impressive regard september company announce launch persona partial knee system be latest addition portfolio personalize anatomically design knee implant system also june zimmer biomet announce release ray base patient specific instrument psi knee system be world first ce marked surgical plan system allow patient specific implant position solely utilize ray technology development be expect boost top line third quarter emerge market have always be significant revenue generate source zimmer biomet recent economic downturn affected zimmer biomet business latin america company manage drive growth operation other part emerge market especially asia pacific emea europe middle east africa zack consensus estimate third quarter revenue emea indicate improvement year quarter overall zimmer biomet expect third quarter revenue range reflect negative impact foreign exchange zack consensus estimate third quarter total revenue be peg however factor macroeconomic uncertainty unfavorable currency fluctuation have be adversely dent zimmer biomet sale past few quarters moreover company have also be deal pricing pressure issue regard zimmer biomet face negative pricing pressure approximately second quarter thus absence favorable change line company continue face headwind be report quarter well meanwhile second half management continue expect adverse impact reduce sale expectation continue spending critical program rise manufacturing cost warsaw north campus facility persist here be quantitative model predict zimmer biomet do not have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp zimmer biomet be uncover best stock buy sell re report earning esp filter zack rank zimmer biomet carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning reflect decline year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank buy see complete list today zack rank strong buy stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
100,ZBH,ever undergo reconstructive orthopedic surgery yes then have be implanted personalize joint replacement technology indiana base lead orthopedic medical device manufacturer zimmer biomet holding inc zbh free report formerly know zimmer holding june legacy zimmer complete acquisition biomet operation more country company market orthopedic reconstructive spinal trauma device biologic dental implant related surgical product more country currently zimmer biomet have zack rank hold change follow second quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate stand share last day zimmer biomet adjust earning share have miss estimate cent zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quoterevenue zimmer biomet post revenue be line zack consensus estimate revenue key stat second quarter revenue derive zimmer knee segment be year year hip record sale compare prior year quarter revenue surgical sport medicine foot ankle extremity trauma improve year year major factor management company increase production output warsaw north campus manufacturing facility continue drive effort achieve best class quality system revenue growth do not meet company expectation due production delay certain key brand slower expect sale recapture previously affected customer unite state company also update sale earning guidance stock price follow earning release share price do not show movement pre market trading session check back later full zimmer biomet earning report later more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
101,ZBH,here be stock add zack rank strong sell list today zimmer biomet holding inc zbh free report be manufacturer marketer musculoskeletal healthcare product solution zack consensus estimate current year earning have be revise downward last day scott miracle gro company smg free report be manufacturer marketer seller consumer lawn garden product globally zack consensus estimate current year earning have be revise downward last day universal health service inc uhs free report be operator acute care hospital behavioral health facility ambulatory center zack consensus estimate current year earning have be revise downward last day first republic bank frc free report be provider private banking real estate lend wealth management service zack consensus estimate current year earning have be revise downward last day alaska air group inc alk free report be provider passenger cargo air transportation service mainly zack consensus estimate current year earning have be revise downward last day view entire zack rank list
102,ZBH,nuvasive inc nuva free report receive expand clearance fda tlx interbody system tlx interbody system be insert conventional transforaminal lumbar interbody fusion tlif approach tlx implant be place easily disc space due low profile bullete design tlx be design minimally invasive spine surgery approach tlx interbody be available degree lordotic option be only indicated use allograft receipt approval accord company new clearance include expandable degree interbody broader indication use include use allogeneic bone graft additional level spine tlx system size offer many option vary patient size anatomic consideration tlx interbody system combine integrate global alignment iga suite company software have ability improve overall tlif procedure notably nuvasive be currently leave stone unturned cash rapidly evolve spine market last report second quarter company core spinal hardware business maintain bullish trend growth upside be drive strong adoption reline posterior fixation system company iga platform company also witness steady uptake recently launch expandable interbody cage base ti interfixated alif procedure meanwhile company recently close acquisition vertera spine start company spine space nuvasive also announce commercial launch lessray software technology system particularly work help address overexposure radiation hospital operate room mostly case minimally invasive spine surgery mis accord report globaldata global market spinal fusion be expect rise cagr consider substantial potential market believe latest development be strategic spine market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report rti surgical rtix free report other today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
103,ZBH,mazor robotic mzor free report recently announce receipt ce mark mazor surgical assurance platform allow company market mazor european union commercial partner medtronic mdt free report management medtronic be responsible marketing system europe platform be display eurospine conference dublin ireland launch mazor have receive encourage demand fact mazor robotic broad product spectrum have be key growth driver mazor last report quarter company receive purchase order surgical guidance system include mazor system renaissance system be mazor primarily major hospital corporation renaissance system order be distribution partner australia thailand mazor robotic system backlog end second quarter totale global basis company end second quarter system worldwide unite state mazor align software earlier year company have announce receipt fda clearance mazor align software software be design assist surgeon plan spinal deformity correction spinal alignment procedure perform mazor surgical assurance platform market prospectswe be encourage opportunity global spine surgery market research report market market suggest niche market reach worth cagr meanwhile company face stiff competition like zimmer biomet holding zbh free report intuitive surgical isrg free report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
104,ZBH,sep article publish duke university nuvasive inc nuva free report have reportedly close acquisition time be start company call vertera spine create research duke university georgia institute technology however financial term deal have not be disclose nuvasive have just extend global headquarter san diego currently focus apply procedurally integrate solution minimally disruptive spine surgery latest development remain part strategy have steadily strengthen nuvasive global position company aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state acquisition have also lend company dimensional porous interbody technology peek titanium material notably company have introduce few new feature modulus xlif build fully porous titanium implant create dimensional manufacturing process well design match porosity stiffness bone be encourage note company spinal hardware business comprise implant fixation product magec eos spinal brace lengthen system precice limb lengthen system register growth recently report quarter nuvasive be therefore leave stone unturned gain traction fast grow spine market regard company have be steadily focuse product development claim possess active corporate development pipeline include number strategic investment acquisition partnership opportunity notably first quarter company launch first interbody device mlx tlx used lumbar fusion procedure report becker spine review global minimally invasive spine surgery market be expect witness cagr also report technavio global spinal implant market be expect witness cagr roughly period thus give current market potential believe company be right track gain traction also believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be also dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report rti surgical rtix free report other notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio zimmer biomet collection thoracolumbar product form comprehensive portfolio minimally invasive spine surgery more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
105,ZBH,indiana base zimmer biomet holding inc zbh free report lead player global musculoskeletal space recently announce second quarter preliminary result company be slate report consolidated quarterly result jul market open zimmer expect second quarter net revenue prior year quarter constant exchange rate cer basis assessed revenue quarter however be line zack consensus estimate moreover figure fall company second quarter revenue guidance reflect rise cer management favorable foreign currency exchange rate have drive number consider basis point contribution ldr hold corporation acquisition adjust expect revenue decline cer remain company earlier project guidance growth cer basis company also expect adjust earning second quarter bottom end project guidance range company expectation be almost line zack consensus estimate management company be still grapple headwind such shortage supply product have lead inability recapture lose customer gain new one positive note production level warsaw facility witness considerable improvement regard note recent past company have be work enhance performance boost market share thus company launch ce marked ray base patient specific instrument psi knee system jun latest development be part lucrative knee business notably knee segment contribute total revenue report first quarter fiscal consider zimmer net ebit synergy company be steadily move goal achieve cumulative target mid roughly cumulative net benefit derive year end demonstrate incremental synergy fiscal preliminary number promising prospect have however fail boost market sentiment moreover market seem be apprehensive departure zimmer decade old ceo david dvorak however mr dvorak continue serve advisory role interim ceo daniel florin currently senior vice president chief financial officer company select suitable person position thus zimmer share be day announcement news zimmer have be lag broader medical instrument market gain compare industry last month however company have outperformed gain market same time frame latest positive news be expect provide impetus company niche market zack rank key pickszimmer currently have zack rank hold few other better rank medical stock be abiom inc abmd free report edward lifescience corporation ew free report align technology inc algn free report notably abiom edward lifescience sport zack rank strong buy align technology carry zack rank buy see complete list today zack rank stock here abiom have long term expect earning growth rate stock have gain last month edward lifescience have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
106,ZBH,effort strengthen global presence nuvasive inc nuva free report be plan renovate extend san diego global headquarters lead medical device company also aim add highly sophisticated innovation center excellence facility nuvasive further plan add world class surgeon education lab apart expand work space company intend introduce educate surgeon globe company highly sophisticated spine technology procedure innovation center excellence nuvasive pioneer apply procedurally integrate solution minimally disruptive spine surgery have be steadily strengthen global position company open center excellence amsterdam be follow build new sq ft medical device facility west carrollton moreover company own sq ft facility be used central distribution hub tn nuvasive have be ride strength international business interestingly company witness year year improvement top line front second quarter account robust growth international business encouragingly note quarter marked third consecutive quarter more growth international business thus company effort solidify global footprint seem be strategically align report becker spine review global minimally invasive spine surgery market be expect witness cagr give current market potential believe company be right track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio moreover zimmer biomet range thoracolumbar product form comprehensive portfolio minimally invasive spine surgery however past month nuvasive share price have underperform industry stock have decline contrast broader industry gain company have also underperform gain market same time frame zack rank key picknuvasive carry zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
107,ZBH,gainesville fl base exactech inc recently announce new product truliant knee system surgical instrumentation have be honor bronze award international design excellence award idea atlanta ga sponsored industrial designer society america idea winner receive significant international publicity exposure idea contest note hundred entry country continent significant development company knee segment truliant knee system offer advanced approach total knee replacement surgery clinically recognize platform proven implant personalize surgical workflow exclusivity truliant system be embed ergonomic instrumentation design enable surgeon make appropriate bone cut adjustment joint total knee arthroplasty last report quarter knee revenue be flat increase constant currency exactech ride solid knee businessin july exactech take step goal provide inclusive range knee replacement system launch exactechgps tka be advanced software application provide systematic computer guidance orthopedic surgeon total knee arthroplasty tka procedure exactech benefit solid prospect total knee replacement market face tough competition like zimmer biomet holding inc zbh free report offer iassist knee personalize guidance system knee replacement procedure exactech plan complete commercial launch tka software application product development be line company objective gain traction huge untapped total knee replacement market datum provide grand view research market be expect reach worth apart solid initiative knee platform exactech announce fda approval market proprietary exactechgps shoulder application unite state earlier year share price trendsover past month exactech have be trading broader industry company stock have gain higher industry believe company be currently ride high regulatory approval product launch however estimate revision trend current quarter lack luster last month notably estimate moved south compare movement opposite direction zack consensus estimate current quarter fall cent share same timeframe exactech have zack rank hold key picksa few better rank stock broader medical sector be edward lifescience corp ew free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy stryker have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return stryker represent impressive year date return stock have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
108,ZBH,aug issue update research report warsaw base zimmer biomet holding inc zbh free report lead musculoskeletal healthcare company design distribute orthopedic reconstructive product spine bone heal thoracic product dental implant related surgical product last month zimmer biomet be trading industry factor macroeconomic uncertainty pricing pressure unfavorable currency fluctuation stock have now lose compare industry gain company deliver dull second quarter result expect downside continue upcoming period management company be still fight headwind such slump knee business shortage supply product thus lead inability recapture lose customer unite state gain new one also trim guidance add concern indicate slim chance recovery ahead market also seem be apprehensive departure zimmer biomet decade old ceo david dvorak notably year tenure zimmer biomet have transform global leader musculoskeletal healthcare combination organic growth strategic acquisition company revenue have double phase have introduce broad portfolio technology solution personalize service only time tell step drovak leave adverse impact company business currently remain sideline further visibility be obtain matter positive note look forward ongoing synergy ldr hold acquisition broaden complement company musculoskeletal offer be line strategy grow inorganic mean focuse mega merger management be also strive develop strong spine portfolio order cash opportunity company spine offering such mobi cervical disc prosthesis vitality spinal fixation system show considerable progress performance zimmer biomet have be late work strengthen foothold emerge market provide long term opportunity company strategic investment region several quarters view enhance operational sale performance be yielding result zack rank key pickszimmer biomet currently carry zack rank sell better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
109,ZBH,here be stock add zack rank strong sell list today zimmer biomet holding inc zbh free report be designer musculoskeletal healthcare product solution zack consensus estimate current year earning have be revise downward last day trueblue inc tbi free report be provider contingent staffing recruitment process outsource contingent staffing management service zack consensus estimate current year earning have be revise downward last day triangle capital corporation tcap free report be business development company zack consensus estimate current year earning have be revise downward last day strayer education inc stra free report be provider range post secondary education other academic program zack consensus estimate current year earning have be revise downward last day maxlinear inc mxl free report be provider radio frequency rf mixed signal circuit zack consensus estimate current year earning have be revise downward last day view entire zack rank list
110,ZBH,zimmer biomet holding inc zbh free report report second quarter adjust earning share ep year year adjust earning be also ahead zack consensus estimate cent reportedly net earning come cent share mark massive increase year loss cent share revenue detailszimmer biomet second quarter net revenue come mark rise constant exchange rate cer year year recently include ldr hold contribute basis point bps top line exclude contribution ldr hold quarter revenue decline year year revenue however remain line zack consensus estimate revenue generate americas quarter touch year year cer same emea europe middle east africa gross asia pacific figure be zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc derive knee be year year cer hip record sale prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record improvement dental be quarter other revenue drop marginswith reduction cost product sell zimmer biomet gross margin expand bps second quarter selling general administrative expense be research development expense increase however adjust operate margin expand bps surge operate profit quarter cash positionzimmer biomet exit second quarter cash cash equivalent first quarter end total long term debt be compare end first quarter year date operate cash flow be compare year period company also paid dividend second quarter outlook base dull topline show zimmer biomet have lower full year guidance company currently expect register revenue growth cer range earlier prediction be include contribution approximately bps ldr transaction current zack consensus estimate revenue be peg adjust ep expectation have be forecast range lower earlier range year current zack consensus estimate ep be peg much ahead current guidance takezimmer biomet end quarter mixed note earning top zack consensus estimate revenue remain line same be disappoint company decline sale performance several core segment trimemd guidance also add concern indicate little chance recovery ahead nevertheless improve gross operate margin performance be encourage look forward expect synergy ldr hold acquisition broaden complement company musculoskeletal offer be also impressed strong strategic financial goal combine entity expect reach now deal have be close zack rank other key pickscurrently zimmer biomet carry zack rank hold better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar last month becton dickinson company have long term expect earning growth rate stock have rally last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
